## Connecting via Winsock to STN

```
Web Page URLs for STN Seminar Schedule - N. America

"Ask CAS" for self-help around the clock
BELISTEIN: Reload and Implementation of a New Subject Area

DEB Will be removed from STN

US Patent Applications available in IFICDB, IFIPAT, and IFIUDB

22 Brootds from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS

23 BIOSIS Gene Names now available in TOXCENTER

Records from IP.com available in TOXCENTER

24 Rederal Research in Progress (FEDRIP) now available

New e-mail delivery for search results now available

DCTFULL has been reloaded

DCTFULL has been reloaded

CORREGE no longer contains STNNDARDS file segment

Saved answer sets no longer valid

Saved answer sets no longer valid

BENJANCHERST to be removed from STN

ANTERIEST to be removed from STN

ANTERIEST to be removed from STN
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         IFIPAT, IFICOB, and IFIUDB have been reloaded
The MEDLINE file segment of TOXCENTER has been reloaded
Sequence searching in REGISTRY enhanced
JAPIO has been reloaded and enhanced
                                                                                                                                                            Welcome to STN International * * * * * * * *
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          February 1 CURRENT WINDOWS VERSION IS V6.0d,
CURRENT MACINTOSH VERSION IS V6.0d ENG) AND V6.0Ja(JP),
AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
STN Operating Hours Plus Help Desk Availability
General Internet Information
Welcome Banner and News Items
Welcome Dain and Telecommunication Network Access to STN
CAS World Wide Web Site (general information)
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           CANCERLIT reload
PHRRWAMArketLetter(PHARWAML) - new on STN
TIS has been reloaded and enhanced
Aquatic Toxicity Information Retrieval (AQUIRE)
now available on STN
Welcome to STN International! Enter x:x
                                                                                                TERMINAL (ENTER 1, 2, 3, OR ?):2
                                   LOGINID: ssspta1642cxy
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Aug 19
Aug 19
Aug 26
Sep 03
                                                                                                                                                                                                                         Apr 08
Apr 09
Apr 09
Apr 19
Apr 22
Apr 22
Apr 22
Jun 10
Jun 10
Jun 10
                                                                                                                                                                                                                                                                                                                                                                                                                                                                          29
30
08
08
19
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Jul
Jul
Aug
Aug
Aug
Aug
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              NEWS EXPRESS
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 NEWS 14
NEWS 15
NEWS 16
NEWS 17
NEWS 18
NEWS 19
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         NEWS 20
NEWS 21
NEWS 22
NEWS 23
                                                                                                                                                                                                                                                                                                                                                                                                         1221
```

Snter NEWS followed by the item number or name to see news on that specific topic.

NEWS HOURS NEWS INTER NEWS LOGIN NEWS PHONE NEWS WWW

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 07:31:47 ON 11 SEP 2002

=> file uspatfull COST IN U.S. DOLLARS  COST IN U.S. DOLLARS  COST IN U.S. DOLLARS  COST IN U.S. DOLLARS  FILE STITMATED COST  CA. INDEXING COPPRIGHT (C) 2002 AMERICAM CHEMICAL SOCIETY (ACS)  FILE COMES 1971 TO PATENT PUBLICATION DATE: 10 Sep 2002 (20020910/PP FILE LAST UPDATED: 10 Sep 2002 (20020910/ED)  FILE LAST UPDATED: 10 Sep 2002 (20020910/ED)  HIGHEST APPLICATION PUBLICATION WHERE. USSA01976  HIGHEST APPLICATION PUBLICATION PUB	TOTAL SESSION 0.21	CS)	: (20020910/PD) JA) (20020910/PD) in 2002	of the  ox  US  Tred in  criginal  c	ther	o d	
ESTIMATED COST  'USPATFULL' EN  MDEXING COPERS  COVERS 1971 TO  COVERS 1971 TO  LAST UPDATED: SST ARANTED PAI  SST ARANTED PAI  SST ARANTED FOR  SST ARANTED FOR  SST ARANTED FOR  SST ARANTAL OF CLA  OSPATZ is now  oxiginal, i.e.  applications;  USPATFULL A  publication of  published down  published down  published down  USPATFULL A  Publication of  Tecords and ma  AFF, etc.  USPATFULL and  ILKNOUGH THE OR  THOUGH THE OR  THOUGH THE OR  THE CONTAINS  CLASSIFICATION  USE USPATALL W  CLASSIFICATION  TO BE HEAT  TO BE HE	SINCE FILE ENTRY 0.21	11 SEP 2002 CHEMICAL SOCIETY (A	ATE: 10 Sep 2002 (2 /ED) US2002124292 02 (20020910/UPCA) GH: 10 Sep 2002 (20 /E): Jun 2002 ID: Jun 2002 IS ISSUE DATE: Jun 2	hed granted patents text of the latest text of the latest the inventions cow ains not only the o of any subsequent ter, patent kind cod lications for an in ormation) field of	d and searched toge Type FILE USPATALL uch as patent assig y potentially changion.	for easy and accura	(W) 70) IN 70
	nll Miars Cost	'' ENTERED AT 07:32:03 ON YRIGHT (C) 2002 AMERICAN	1 TO PATENT PUBLICATION D ED: 10 Sep 2002 (20020910) PATENT NUMBER: US6.487:8 CHERENT THROUGH 10 Sep 20 LIDS (/NCL) CHERENT THROU LIDSS (/NCL) LAST ERLOADED CLASSIFICATIONS THESAURU CLASSIFICATIONS THESAURU	i.e., the earliest publis in a. the earliest publis one. USPATZ contains full mis, starting in 2001, for A USPATFULL record cont document but also a list one. The publication numben date for all the US pub yed in the PI (Patent Inf d may be searched in stand d may be searched in stand in the property of the property	and USPAT2 can be accesse e new cluster USPATALL. cluster. Li when searching terms s tions, or claims, that ma st to the latest publicat	ins CAS Registry Numbers ification.	HEATS HEATS HEATS HEATS HEATS HEATS HEAT OR HEATS) SHOCKS SHOCKS SHOCK SHOCK OR SHOCKS) PROTEINS PROTEINS PROTEINS PROTEINS PROTEINS HEAT SHOCK PROTEIN 70 (PROTEIN OR PROTEIN 70 HEAT SHOCK PROTEIN 70 UVANIT ADJUVANT
	=> file uspatfu COST IN U.S. DO FULL ESTIMATED	FILE 'USPATFULL CA INDEXING COP	FILE COVERS 197 FILE LAST UPDAT HIGHEST GRANTED HIGHEST APPLICAS CA INDEXING IS ISSUE CLASS FIE REVISED CLASS FE USPTO MANUAL OF			file	s hsp70 or h 776260 473540 131043 143087 143087 118760 97209 138809 1234377 1234377 1234377 1234377 1234373 820

54394 ADJUVANT

(ADJUVANT OR ADJUVANTS)

about rem 12 PROCESSING COMPLETED FOR L2 L3 340 DUP REM L2 (0 DUPLICATES REMOVED)

8 13 not py=>1999 340 S L3

816008 PY=>1999 46 L4 NOT PY=>1999

ţ.; Ľ, d 15 1-10 ab ĥ S E

ANSWER 1 OF 46 USPATFULL.
A protein, Leukocyte Derived Growth Factor 2 (hereinafter LDGF2) having PDGF-like activity is described. LDGF2 reacts with PDGF receptors and possesses mitogonic and/or chemotactic activity for various cell types, particularly connective fissue cells. LDGF2 may be used as the active ingredient in therapeutic compositions, e.g. wound healing compositions, or even further may be used as an additive to cell culture media for the purpose of stimularing cell growth. The protein has a molecular weight of about 7000 daltons determined by SDS gel electrophoresis and is about 61 mmino acids in length.

PB ES

ANSWER 2 OF 46 USPATFULL
Disclosed is a Drosophila grim gene and encoded GRIM polypeptide, an activator of apoptosis. The disclosed nucleic acid sequences are useful in the production of the protein and as hybridization probes and primers. Expression of the GRIM protein causes programmed cell death. Preferred embodiments include expression of grim under the control of an inducible promoter and the use of such a construct in the control of an insect population.

5 2

Disclosed is a method for determining whether a test protein is capable of interacting with a nuclear hormone receptor protein. The method involves: (a) providing a host cell which contains (i) a reporter gene operably linked to a protein binding site; (ii) a first fusion gene which expresses a first fusion protein, the first fusion protein including a nuclear hormone receptor protein covalently bonded to a binding site; and (iii) a second fusion gene which expresses a second fusion protein, the second fusion protein including the test protein covalently bonded to a weak gene activating moiety; and (b) determining whether the test protein increases expression of the reporter gene as an indication of its ability to interact with the nuclear hormone receptor protein. Such an interaction may be hormone dependent, hormone independent, or hormone sensitive. Also disclosed is purified DNA encoding thyroid hormone receptor—interacting proteins and the

ANSWER 4 OF 46 USPATFULL 52

The present invention concerns the discovery that proteins encoded by a family of vertebrate genes, termed here hedgehog-related genes, comprise morphogenic signals produced by embryonic patterning centers, and are involved in the formation of ordered spatial arrangements of differentiated tissues in vertebrates. The present invention makes available compositions and methods that can be utilized, for example to generate and/or maintain an array of different vertebrate tissue both in vitro and in vivo.

ANSWER 5 OF 46 USPATFULL 5

The present invention relates to the use of a group of propargylamines of the general formula (1) ##STR1## wherein R. sup.1 is hydrogen or CH.sub.3 and R.sup.2 is (CH.sub.2).sub.n CH.sub.3 and nist an integer from 0 to 16, and salts thereof, as cellular rescue agents in the treatment and prevention of diseases in which cell death occurs by apoptosis. Some of the compounds of formula 1 are novel. The invention is also directed to the use of these compounds in the treatment of these diseases, as well as to processes for the preparation of the compounds.

ЯВ

USPATFULL ANSWER 6 OF 46

The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases. The methods of the invention complate administering a composition comprising an effective amount of a complex, in which the complex consists essentially of a heat shock protein (hsp) noncovalently bound to an antigenic molecule. "Antigenic molecule" as used herein refers to the peptides with which the hsps are endogenously associated in vivo as well as exogenous antigens/immunogens (i.e., with which the hsps are not the recomplexed in vivo) or antigenic/immunogenic fragments and derivatives thereof. In a preferred embodiment, the complex as autologous to the individual. The effective amounts of the complex are in the range of 10.600 micrograms for complexes comprising hsp70, 50-1000 micrograms for complexes comprising hsp70, 50-1000 provides a method for measuring tumor rejection in vivo in an individual, preferably a human, comprising measuring the generation by the individual of MiC Class I-restricted CD8+ cytotoxic I lymphocytes complexes are also provided.

USPATFULL ANSWER 7 OF 46 P P

Methods and compositions for treating CF by mobilizing mutant forms of CFTR, which retain at least some functional activity, to the plasma membrane where they can mediate chloride ion transport are disclosed.

USPATFULL ANSWER 8 OF 46

The present invention provides a human cofactor A-like protein (COAPR) and polynucleotides which identify and encode COAPR. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of COAPR. AB ES

ANSWER 9 OF 46 USPATFULL

S E

Attended vaccinia or canarypox recombinant viruses containing DNA coding for a cytokine and/or a tumor associated antigen as well as methods and compositions employing the viruses, are disclosed and claimed. The recombinant viruses can be NVVAC or ALVAC recombinant viruses. The DNA can code for at least one of: human tumor necrosis factor; nuclear phosphoprotein p53, wildtype or mutant; human melanoms, nuclear phosphoprotein p53, wildtype or mutant; human melanoms associated antigen; IL-2: IFN.gamma.; IL-4; GMCSF; IL-12; B7; erb-b-2 and carcinoembryonic antigen. The recombinant viruses and gene products therefrom are useful for cancer therapy.

ANSWER 10 OF 46 USPATFULL P P

The present invention relates to recombinant mycobacteria, particularly recombinant M. bovis BCG, which express heterologous DNA encoding a product (protein or polypeptide) of interest, such a protein or polypeptide (e.g., an antigen) against which an immune response is desired, or a cytokine.

=> d 1-10 ibib

ANSWER 1 OF 46 57 1998:157146 USPATFULL
DNA encoding leukocyte derived growth factor-2 (LDGF-2)
Grotendorst, Gary R., Miami, FL, United States
Iida, Naoko, Miami Beach, FL, United States
University of South Florida, Tampa, FL, United States
(U.S. corporation) US 584954

US 1995-465095

US 1995-465095

US 1995-465095

US 1994-179656, filed on 7 Jan
1994 which is a continuation-in-part of Ser. No. US
1993-1177, filed on 7 Jan 1993, now abandoned which is
a continuation-in-part of Ser. No. US
filed on 1 Feb 1990, now abandoned
Utility Nuclear hormone receptor-interacting polypeptides and related molecules and methods Moore, David D., Hingham, MA, United States Lee, Jae Moon, Somerville, MA, United States The General Hospital Corporation, Boston, MA, United States (U.S. corporation) USPATFULL

1998:154085 USPATFULL

INVERTEDIATE apoptosis gene 'CRIM' and methods of producing the protein encoded thereby
Abrams, John M., Dallas, TX, United States
Chen, Po, Dallas, TX, United States
Nordstron, William, Dallas, TX, United States
Board of Regents, The University of Texas System, Austin, TX, United States Kemmerer, Elizabeth C. Lahive & Cockfield, LLP, DeConti, Jr., Giulio A., Lanley, Elizabeth A. 1 24 Drawing Figure(s); 18 Drawing Page(s) 10 Drawing Figure(s); 2 Drawing Page(s) 8 19981208 19960722 DATE DATE KIND KIND KIND USPATFULL 1998:154029 USPATFULL Kemmerer, Elizabeth C. Arnold, White & Durkee LINE COUNT: 1666
CAS INDEXING IS AVAILABLE FOR THIS PATENT. LINE COUNT: 2475
CAS INDEXING IS AVAILABLE FOR THIS PATENT. US 5846768 US 1996-684101 Utility Granted NUMBER NUMBER NUMBER FILE SEGMENT:
PRIMARY EXAMINER:
LEGAL REPRESENTATIVE:
MINBER OF CLAIMS:
EXEMPLARY CLAIM:
NUMBER OF DRAMINGS: PATENT INFORMATION: APPLICATION INFO.: RELATED APPLN. INFO.: LEGAL REPRESENTATIVE: LS ANSWER 3 OF 46 ACCESSION NUMBER: LS ANSWER 2 OF 46 ACCESSION NUMBER: PATENT ASSIGNEE(S): EXEMPLARY CLAIM: NUMBER OF DRAWINGS: LINE COUNT: PATENT ASSIGNEE(S): PATENT INFORMATION: PATENT ASSIGNEE (S): APPLICATION INFO.: DOCUMENT TYPE: ACCESSION NUMBER: NUMBER OF CLAIMS: FILE SEGMENT: PRIMARY EXAMINER: DOCUMENT TYPE: TITLE: INVENTOR(S): INVENTOR (S): INVENTOR (S): TITLE:

8

19981208

US 5846711 US 1994-222719

PATENT INFORMATION: APPLICATION INFO:

Continuation-in-part of Ser. No. US 1992-969136, filled on 30 Oct 1992, now abandoned Utility Granted Carlson, Karen Cochrane Clark & Elbing LLP 5 1 39 Drawing Figure(s); 37 Drawing Page(s) 1810 LBLE FOR THIS PATENT.	USPATFULL 1998:151078 USPATFULL Vertebrate embryonic pattern-inducing proteins, and uses related thereto Ingham, Philip W., Summertown, England McMahon, Andrew P., Lexington, MA, United States Tabin, Clifford J., Cambridge, MA, United States President and Fellows of Harvard College, Cambridge, MA, United States	US 5844079 US 5844079 US 1994-35606 US 1994-35606 Continuation-in-part of Ser. No. US 1993-176427, filed Continuation-in-	USPATFULL  1998:147687 USPATFULL  Aliphatic propargylamines as cellular rescue agents Durden, David, Saskatoon, Canada Paterson, Alick, Saskatoon, Canada Davis, Bruce, Saskatoon, Canada Davis, Lillian, Saskatoon, Canada Yu, Peter, Saskatoon, Canada Li, Xinmin, Saskatoon, Canada Li, Ximmin, Saskatoon, Canada University of Saskatoon, Canada University of Saskatchewan, Saskatoon, Canada Corporation)	NUMBER KIND DATE US 5840979 19981124 US 1397-891904 19970714 (8) Utility Utility Cranted Burn, Brian M. Synnestvedt & Lechner 9 1 4 Drawing Figure(s); 2 Drawing Page(s)
RELATED APPLN. INFO:: Continuation on 30 Oct: DOCUMENT TYPE: Utility FILE SECHENT: Granted PRIMARY EXAMINER: Carlson, Kalecal Representative; Clark & Elb NUMBER OF CLAIMS: EXEMPLARY CLAIM: 1 SHOUNDER OF DRAWINGS: 39 Drawing LINE COUNT: 1810 CAS INDEXING IS AVAILABLE FOR THIS	LS ANSWER 4 OF 46 ACCESSION NUMBER: TITLE: INVENTOR(S): PATENT ASSIGNEE(S):	PATENT INFORMATION: US APPLICATION INFO.: US RELATED APPLN. INFO.: CG DOCUMENT TYPE: UT FILE SEGMENT: FILE SEGMENT: FILE SEGMENT: RASISTANT EXAMINER: SG LEGAL REPRESENTATIVE: Vi LEGAL REPRESENTATIVE: Vi NUMBER OF CLAIMS: 41 NUMBER OF DRAWINGS: 22 LINE COUNT: 76 CAS INDEXING IS AVAILABLE	LIS ANSWER S OF 46 ACCESSION NUMBER: TITLE: INVENTOR(S): PATENT ASSIGNEE(S):	PATENT INFORMATION: APPLICATION INFO.: DCCUMBNT TYPE: FILE SEGMEN: PRIMARY EXAMINER: IEGAL REPRESENTATIVE: NUMBER OF CLAIMS: EXEMPLARY CLAIMS: NUMBER OF DRAWINGS:

LINE COUNT:
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

R: S: S: VAILABL 46 USP ():	NUMBER KIND DATE US 5837251 US 1995-527391
ER: INGS: MS: INGS: INGS: CoF 46 USP ER: E(S): F(S):	Granted Tsang, Cecilia J.  Celsa, Bennett 6 1 Drawing Figure(s); 9 Drawing Page(s) 635 ABLE FOR THIS PATENT. 1998.138682 USPATFULL 1999.13682 USPATFULL 1999.1368 CA, United States Goll, Surya K., Sumnyvale, CA, United States Goll, Surya K., Sumnyvale, CA, United States Granted 1997.825782 1997408 (8) US 583.2392 1997408 (8) US AND ARE US SESSER USPATFULL 1997.825782 19970408 (8) US CARLED 1997.825782 19970408 (8)

Romeo, David S.  Romeo, David S.  Pharmaceuticals, Inc.  Bharmaceuticals, Inc.  J Drawing Figure(s); 3 Drawing Page(s)  Brawing Figure(s); 3 Drawing Page(s)  Branch S.  S. S. S. S. S. S. S. S. S. S. S. S. S. S	NUMBER KIND DATE US 5833975 19981110 US 5833975 19981110 US 1994-184009 US 1994-184009 21 Jan 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-847951, filed on 6 Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-713967, filed continuation-in-part of Ser. No. US 1991-713967,	on 11 Jun 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-666056, filed on 7 Mar 1991, now abandoned said Ser. No. US 7115 which is a continuation-in-part of Ser. No. US 1991-805567, filed on 16 Dec 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-638080, filed on 7 Jan 1991, now abandoned said Ser. No. US 7115 which is a continuation-in-part of Ser. No. US 7115 which is a continuation-in-part of Ser. No. US 1992-847977, filed on 3 Mar 1992, now abandoned which is a division of Ser. No. US 1990-478179, filed on 14 Feb 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-130411, filed on 8 Mar 1989, now Utility (Ser. No. US 5155020 Utility (Granted Crouch, Deborah Frommer Lawrence & Haug LLP, Frommer, William S., Kowalski, Thomas J.	5 1 46 Drawing Figure(s); 33 Drawing Page(s) 8834 ABLE FOR THIS PATENT.	USPATFULL 1998:134636 USPATFULL Recombinant mycobacterial vaccines Aldovini, Anna, Winchester, MA, United States Young, Richard A., Winchester, MA, United States Whitehead Institute for Biomedical Research, United States (U.S. corporation)	NUMBER KIND DATE US 5830475 19981103 US 1995-460981 19950605 (8)
ASSISTANT EXAMINER: BCGAL REPRESENTATIVE: NUMBER OF CLAIMS: FXEMPLARY CLAIM: NUMBER OF DRAWINGS: LINE COUNT: LINE COUNT: ACCESSION NUMBER:	PATENT INFORMATION: APPLICATION INFO.: RELATED APPLN. INFO.:	DOCUMENT TYPE: FILE SEGMENT: PRIMARY EXAMINER: LEGAL REPRESENTATIVE:	NUMBER OF CLAIMS: 5 EXEMPLARY CLAIM: 1 NUMBER OF DRAWINGS: 46 LINE COUNT: 86 CAS INDEXING IS AVAILABLE	L5 ANSWER 10 OF 46 ACCESSION NUMBER: TITLE: INVENTOR(S): PATENT ASSIGNEE(S):	PATENT INFORMATION: APPLICATION INFO.:

Continuation of Ser. No. US 1993-96027, filed on 22 Jul 1993, now patented, Pat. No. US 5591632 which is a continuation-in-part of Ser. No. US 1991-111334, filed on 6 Jun 1991, now abandoned which is a continuation-in-part of Ser. No. US 1999-367894, filed on 19 Jun 1989, now abandoned, said Ser. No. US 711334 which is a continuation-in-part of Ser. No. US 504005 which is a continuation-in-part of Ser. No. US 1988-233099, filed on 2 Jul 1988, now abandoned And Ser. No. US 1988-216390, filed on 7 Jul 1988, now abandoned which is a continuation-in-part of Ser. No. US 1988-16350, filed on 7 Jul 1988, now abandoned, said Ser. No. US 220089 which is a continuation-in-part of Ser. No. US 1988-16364, filed on 3 Mar 1988, now abandoned, said Ser. No. US 221089 which is a continuation-in-part of Ser. No. US 1987-20451, filed on 2 Mar 1987, now abandoned. Elliott, George C. Railey, II, Johnny F. Hamilton, Brook, Smith & Reynolds, P.C. Granted PRIMARY EXAMINER:
ASISTANT EXAMINER:
LEGAL REPERENTATIVE:
NUMBER OF CLAIMS:
EXEMPLARY CLAIMS:
NUMBER OF DRAWINGS:
LINE COUNT: RELATED APPLN. INFO.:

## d 1-10 ibib ab

20 Drawing Figure(s); 10 Drawing Page(s) 1170

CAS INDEXING IS AVAILABLE FOR THIS PATENT

A protein, Leukocyte Derived Growth Factor 2 (hereinafter LDGF2) having PDGF-like activity is described. LDGF2 reacts with PDGF receptors and possesses mitogenic and/or chemotactic activity for various cell types, particularly connective tissue cells. LDGF2 may be used as the active ingredient in therapeutic compositions, e.g. wound healing compositions, or even further may be used as an additive to cell culture media for the 1998:157146 USPATFULL
DNA encoding leukocyte derived growth factor-2 (LDGF-2)
Grotendorst, Gary R., Miami, FL, United States
Lida, Naoko, Miami Beach, FL, United States
University of South Florida, Tampa, FL, United States
(U.S. corporation) US 5849534

US 1995-465095

US 1995-66095

Division of Ser. No. US 1994-179656, filed on 7 Jan 1994 which is a continuation-in-part of Ser. No. US 1994-1177, filed on 7 Jan 1993, now abandoned which is a continuation-in-part of Ser. No. US 1990-472377, filed on 1 Feb 1990, now abandoned US 1990-472377, Utiliad on 1 Feb 1990, now abandoned Kemmerer, Elizabeth C. Lahive & Cockfield, LLP, DeConti, Jr., Giulio A., Hanley, Elizabeth A. 24 Drawing Figure(s); 18 Drawing Page(s) DATE KIND EXEMPLARY CLAIM:

NUMBER OF DRAWINGS: 24 Drawing Figure(.
LINE COUNT: 1666
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A POTCHAIN, Leukocyte Derived Growth NUMBER Granted USPATFULL PATENT INFORMATION: APPLICATION INFO.: RELATED APPLN. INFO.: FILE SEGMENT: PRIMARY EXAMINER: LEGAL REPRESENTATIVE: L5 ANSWER 1 OF 46
ACCESSION NUMBER: PATENT ASSIGNEE(S): NUMBER OF CLAIMS: DOCUMENT TYPE: INVENTOR(S):

purpose of stimulating cell growth. The protein has a molecular weight of about 7000 daltons determined by SDS gel electrophoresis and is about 61 amino acids in length.

Disclosed is a Drosophila grim gene and encoded GRIM polypeptide, an activator of apoptosis. The disclosed nucleic acid sequences are useful in the production of the protein and as hybridization probes and primers. Expression of the GRIM protein causes programmed cell death. Preferred embodiments include expression of grim under the control of an inducible promoter and the use of such a construct in the control of an Invertebrate apoptosis gene 'GRIM' and methods of producing the protein encoded thereby Abrams. John M. Dallas, TX, United States Nordebrom, Po. Dallas, TX, United States Nordebrom, William, Dallas, TX, United States Board of Regents, The University of Texas System, Austin, TX, United States 10 Drawing Figure(s); 2 Drawing Page(s) (8) 19981208 19960722 Kemmerer, Elizabeth C. Arnold, White & Durkee 22 1998:154085 USPATFULL NUMBER OF CLAINS:

EXEMPLARY CLAINS:

1
NUMBER OF DRAWINGS:

10 Drawing Figure (f. LINE COUNT:

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed is a Drosophila grim gene US 5846768 US 1996-684101 Utility NUMBER Granted insect population. LEGAL REPRESENTATIVE: L5 ANSWER 2 OF 46
ACCESSION NUMBER:
TITLE: PATENT ASSIGNEE(S): PATENT INFORMATION: APPLICATION INFO.: PRIMARY EXAMINER: DOCUMENT TYPE: FILE SEGMENT: INVENTOR (S):

1998-154029 USPATFULL.
Nuclear hormone receptor-interacting polypeptides and related molecules and methods methods whore, David D. Hingham, MA. United States
Lee, Jae Woon, Somerville, MA. United States
The General Hospital Corporation, Boston, MA, United States (U.S. corporation) USPATFULL L5 ANSWER 3 OF 46 ACCESSION NUMBER: TITLE: PATENT ASSIGNEE(S): INVENTOR (S):

US 5846711 US 1994-222719 Continuation-in-part of Ser. No. US 1992-969136, filed on 30 Oct 1992, now abandoned Utility 39 Drawing Figure(s); 37 Drawing Page(s) DATE Granted Carlson, Karen Cochrane Clark & Elbing LLP EXEMPLARY CLAIM:

NUMBER OF DRAWINGS:
39 Drawing Figure (
LINE COUNT:
1810
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB DISCLOSED is a method for determinity NUMBER RELATED APPLN. INFO.: LEGAL REPRESENTATIVE: NUMBER OF CLAIMS: PATENT INFORMATION: PRIMARY EXAMINER: DOCUMENT TYPE: SEGMENT APPLICATION

Disclosed is a method for determining whether a test protein is capable of interacting with a nuclear hormone receptor protein. The method involves: (a) providing a host cell which contains (i) a reporter gene operably linked to a protein binding site; (ii) a first fusion gene which expresses a first fusion protein, the first fusion protein

including a nuclear hormone receptor protein covalently bonded to a binding moiety which is capable of specifically binding to the protein binding site; and (iii) a second fusion gene which expresses a second fusion protein, the second fusion protein including the test protein covalently bonded to a weak gene activating moiety; and (b) determining whether the test protein increases expression of the reporter gene as an indication of its ability to interact with the nuclear hormone receptor independent, or hormone sensitive. Also disclosed is purified DNA encoding thyroid hormone receptor-interacting proteins and the polypeptides expressed from such DNA.

Vertebrate embryonic pattern-inducing proteins, and uses related thereto inflama, Philip W. Summertown, England McMahon, Andrew P., Lexington, MA, United States Tabin, Clifford J., Cambridge, MA, United States MA, United States (U.S. corporation) DATE NUMBER USPATFULL PATENT INFORMATION: APPLICATION INFO.: RELATED APPLN. INFO.: LS ANSWER 4 OF 46 ACCESSION NUMBER: TITLE: PATENT ASSIGNEE(S): INVENTOR (S):

Walsh, Stephen Sorensen, Kenneth H. Vincent, Matthew P., Arnold, Beth B.Foley, Hoag & Ellot LLP US 5844079 19981201 US 1994-356060 19941214 (8) Continuation-in-part of Ser. No. US 1993-176427, filed on 30 Dec 1993 Utility Granted PRIMARY EXAMINER: ASSISTANT EXAMINER: LEGAL REPRESENTATIVE: NUMBER OF CLAIMS: DOCUMENT TYPE: FILE SEGMENT:

Aliphatic propargylamines as cellular rescue agents
Aliphatic propargylamines as cellular rescue agents
Durden, David, Saskatoon, Canada
Paterson, Alick, Saskatoon, Canada
Davis, Bruce, Saskatoon, Canada
Dovk, Lillian, Saskatoon, Canada
Yu, Peter, Saskatoon, Canada
Li, Xinmin, Saskatoon, Canada
Boulton, Alan, Saskatoon, Canada
University of Saskatchewan, Saskatoon, Canada
University of Saskatchewan, Saskatoon, Canada L5 ANSWER 5 OF 46 USPATFULL ACCESSION NUMBER: 1998:1 vitro and in vivo. PATENT ASSIGNEE(S): INVENTOR(S):

19981124 DATE KIND US 5840979 PATENT INFORMATION

1998:138855 USPATFULL

L5 ANSWER 7 OF 46 USPATFULL ACCESSION NUMBER: 1998:13

DECORNITY TYPE:  DELICATION INFO: DELICATION INFO: DELICATION INFO: DELICATION INFO: DELICATION INFO: DELICATION DELICATI
--

Methods and compositions for treating cystic fibrosis Cheng, Seng Hing, Wellesley, MA, United States Jiang, Camwen, Marlboro, MA, United States Genzyme Corporation, Framingham, MA, United States (U.S. corporation) 9 Drawing Figure(s); 9 Drawing Page(s) 19981110 19970227 DATE KIND FILE SEGNAT: Granted
FILE SEGNAT: Granted
FILE SEGNAT: Granted
ASSISTANT EXAMINER: Celsa, Bennett
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Figure(s);
LINE COUNT: 6
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods and commonstrice. US 5834421 US 1997-807398 Utility NUMBER PATENT ASSIGNEE(S): PATENT INFORMATION: APPLICATION INFO.: DOCUMENT TYPE: INVENTOR (S):

Methods and compositions for treating CF by mobilizing mutant forms of CFTR, which retain at least some functional activity, to the plasma membrane where they can mediate chloride ion transport are disclosed.

Polynucleotides encoding a cofactor A-like protein Hillman, Jennifer L., San Jose, CA, United States Goli, Surya K., Sunnyvale, CA, United States Grif, Surya R., Sunnyvale, CA, United States (Goli, Sure Pharmaceuticals, Inc., Palo Alto, CA, United States (U.S. corporation) USPATFULL LS ANSWER 8 OF 46 ACCESSION NUMBER: TITLE: PATENT ASSIGNEE (S): INVENTOR (S):

Kemmerer, Elizabeth C.
Romeo, David S.
Mohan-Peterson, Sheela, Billings, Lucy J.Incyte 8 19981110 19970408 DATE XIND US 5834239 US 1997-825782 Utility NUMBER Granted ASSISTANT EXAMINER: LEGAL REPRESENTATIVE: PATENT INFORMATION: APPLICATION INFO.: FILE SEGMENT: PRIMARY EXAMINER: DOCUMENT TYPE:

Pharmaceuticals, Inc EXEMPLARY CLAIM: NUMBER OF DRAWINGS: NUMBER OF CLAIMS:

3 Drawing Figure(s); 3 Drawing Page(s) 1933 LINE COUNT:
1933
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides a hu

The present invention provides a human cofactor A-like protein (COAPR) and polymucleotides which identify and encode COAPR. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of COAPR.

USPATFULL LS ANSWER 9 OF 46 ACCESSION NUMBER:

1998:138427 USPATFULL canaryox virus expressing cytokine and/or tumor-associated antigen DNA sequence Paoletti, Enzo, Delmar, NY, United States Tartaglia, James, Schenectady, NY, United States Cox, William I., Troy, NY, United States Cox, William I., Troy, NY, United States Corporation, Troy, NY, United States (U.S. corporation) PATENT ASSIGNEE(S): INVENTOR (S):

DATE KIND

US 5833975
US 1994-184009
US 19954-184009
US 19959
US 1955020
US 1969
US 1969 LINE COUNT:

AB Attenuated vaccinia or canarypox recombinant viruses containing DNA and Attenuated vaccinia or canarypox recombinant viruses containing DNA coding for a cytokine and/or a tumor associated antigen, as well as methods and compositions employing the viruses, are disclosed and cathods and compositions employing the viruses are disclosed and claimed. The recombinant viruses can be NYVAC or ALVAC recombinant viruses. The DNA can code for at least one of: human tumor necrosis actor, nuclear phosphoprotein p53, wildtype or mutant; human melanoma-associated antigen; IL-2; IRV.gamma.; IL-4; GMCSF; IL-12; B7; erb-2 and carcinoembryonic antigen. The recombinant viruses and gene products therefrom are useful for cancer therapy. 46 Drawing Figure(s); 33 Drawing Page(s) DOCUMENT TYPE: FILE SEGMENT: PRIMARY EXAMINER: LEGAL REPRESENTATIVE: PATENT INFORMATION: APPLICATION INFO.: RELATED APPLN. INFO.: EXEMPLARY CLAIM: NUMBER OF DRAWINGS: NUMBER OF CLAIMS:

Recombinant mycobacterial vaccines
Aldovini, Anna, Winchester, MA, United States
Young, Kichard A., Winchester, MA, United States
Mitchead Institute for Biomedical Research, United
States (U.S. corporation) 1998:134636 USPATFULL USPATFULL ANSWER 10 OF 46 ACCESSION NUMBER: INVENTOR (S):

PATENT ASSIGNEE(S):

US 5830475

US 1995-460981

Continuation of Ser. No. US 1993-56627, filed on 22 Jul 1993. now patented, Pat. No. US 1993-56627, filed on 22 Jul 1993. now patented, Pat. No. US 5591632 which is a continuation-in-part of Ser. No. US 1993-711334, filed on 6 Jun 1991, now abandoned which is a Continuation-in-part of Ser. No. US 1989-367894, filed on 19 Jun 1989, now abandoned , said Ser. No. US 711334 which is a continuation-in-part of Ser. No. US 5504005 which is a continuation-in-part of Ser. No. US 5504005 which is a continuation-in-part of Ser. No. US 1988-223089, filed on 2 Jul 1988, now abandoned And Ser. No. US 1988-216390, filed on 7 Jul 1988, now abandoned And Ser. No. US 1988-216390, filed on 7 Jul 1988, now abandoned which is a continuation-in-part of Ser. No. DATE KIND NUMBER APPLICATION INFO.: RELATED APPLN. INFO.: PATENT INFORMATION:

us 1988-163546, filed on 3 Mar 1988, now abandoned, said Ser. No. US 223089 which is a continuation-in-part of Ser. No. US 163546 which is a continuation-in-part abandoned
ULILITY 20 Drawing Figure(s); 10 Drawing Page(s) Granted Elliott, George C. Railey, II, Johnny F. Hamilton, Brook, Smith & Reynolds, P.C. FILE SEGMENT: Granted
FRINARY EXAMINER: Elliott, George C.
ASSISTANT EXAMINER: Railey, II, Johnny F.
LEGAL REPRESENTATIVE: Hamilton, Brook, Smit
NUMBER OF CLAIM: 1
NUMBER OF DRAWINGS: 20 Drawing Figure(s);
LINE COUNT: 170
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to recom

=> d his

The present invention relates to recombinant mycobacteria, particularly recombinant M. bovis BCG, which express heterologous DNA encoding a product (protein or polypeptide) of interest, such a protein or polypeptide (e.g., an antigen) against which an immune response is desired, or a cytokine.

FILE 'USPATFULL' ENTERED AT 07:32:03 ON 11 SEP 2002 820 S HSP70 OR HEAT SHOCK PROTEIN 70 340 S.L1 AND ADJUVANT 340 DUP REM L2 (0 DUPLICATES REMOVED) 340 S.L3 NOT PY=>1999 (FILE 'HOME' ENTERED AT 07:31:47 ON 11 SEP 2002) 33233

⇒ d 15 10-20 ibib ab

US 5830475
US 1995-46091
US 1995-46091
US 1995-46091
Continuation of Ser. No. US 1995-96027, filed on 22 Jul 1993. now patented, Pat. No. US 5991632 which is a continuation-in-part of Ser. No. US 1991-711334, filed on 6 Jun 1991. now abandoned which is a continuation-in-part of Ser. No. US 1989-367894, filed on 19 Jun 1989, now abandoned, said Ser. No. US 711334 which is a continuation-in-part of Ser. No. US 1989-36194, filed on 5 Jun 1989, now patented, Pat. No. US 5804005 which is a continuation-in-part of Ser. No. US 1988-213089, filed on 2 Jul 1988, now abandoned And Ser. No. US 1988-213089, filed on 7 Jul 1988, now abandoned which is a continuation-in-part of Ser. No. US 1988-16546, filed on 3 Mar 1988, now abandoned, said Ser. No. US 223089 which is a continuation-in-part of Ser. No. US 1988-16346, which is a continuation-in-part of Ser. No. US 1988-16346, filed on 3 Mar 1988, now abandoned, said Ser. No. US 1987-20451, filed on 2 Mar 1987, now 1998-134636 USPATFULL Recombinant mycobacterial vaccines Aldovini, Anna, Winchester, MA, United States Young, Richard A., Winchester, MA, United States Withehead Institute for Biomedical Research, United States (U.S. corporation) DATE KIND NUMBER USPATFULL LS ANSWER 10 OF 46
ACCESSION NUMBER: APPLICATION INFO.: RELATED APPLN. INFO.: PATENT ASSIGNEE(S): PATENT INFORMATION: INVENTOR (S):

USPATFULL 1998:131609 USPATFULL In vitro activation of cytotoxic T cells

46

L5 ANSWER 12 OF ACCESSION NUMBER: TITLE:

of Ser. No of Ser. No abandoned

The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases. The methods of the invention compists eduninistering a composition comprising an effective amount of a complex, in which the complex consists essentially of a heat shock protein (hsp) noncovalently bound to an antigenic molecule in combination with administering antigen presenting cells sensitized with complexes of hsps noncovalently bound to an antigenic molecule. Antigenic molecule as used herein refers to the peptides with which the hsps are endogenously associated in vivo as well as exogenous antigens(immunogens (i.e., with which the hsps are not complexed in vivo) or antigenic/immunogenic fragments and derivatives thereof. In a preferred embodiment, the effective amounts of the complex when administered mitradermally are in the range of 0.1 to 9.0 micrograms for complexes comprising hap70, 5 to 49 micrograms for knsp0, and 0.1 to 9.0 micrograms for complexes comprising hered subodiment, the effective amounts of the complexe send administered subodiment, the state of the bodiment, the effective amounts of the complexe send administered subodiment, the state of 10 to 9.0 micrograms for complexes comprising here of 10 to 600 micrograms for complexes comprising here of 10 to 600 micrograms for complexes comprising here of 10 to 600 micrograms for complexes comprising here of 10 to 600 micrograms for complexes comprising here of 10 to 600 micrograms for complexes comprising here of 10 to 600 micrograms for complexes comprising here of 10 to 600 micrograms for complexes compressed comprising here of 10 to 600 micrograms for complexes compressed compressed complexes of 10 to 600 micrograms for complexes compressed compressed complexes of 10 to 600 micrograms for complexes compressed compressed complexed for 10 to 600 micrograms for complexed for 10 to 600 micrograms for 10 to 600 micrograms for 10 to 600 micrograms for 10 The present invention relates to recombinant mycobacteria, particularly recombinant M. bovis BCG, which express heterologous DNA encoding a product (protein or polypeptide) of interest, such a protein or polypeptide (e.g., an antigen) against which an immune response is desired, or a cytokine. USPATFULL
1998:134628 USPATFULL
Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive States (U.S. United States 20 Drawing Figure(s); 10 Drawing Page(s) Elliott, George C. Railey, II, Johnny F. Hamilton, Brook, Smith & Reynolds, P.C. Srivastava, Pramod K., Riverdale, NY, Fordham University, Bronx, NY, United 8 19981103 DATE US 5830464
US 1997-796316
Utility
Granted
Saunders, David
VanderVegt, F. Pierre
Pennie & Rômonds Lipe KIND LINE COUNT:

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to me LINE COUNT: 1170
CAS INDEXING IS AVAILABLE FOR THIS PATENT. immunotherapy corporation) NUMBER ASSISTANT EXAMINER: LEGAL REPRESENTATIVE: NUMBER OF CLAIMS: EXEMPLARY CLAIM: LEGAL REPRESENTATIVE: NUMBER OF CLAIMS: EXEMPLARY CLAIM: NUMBER OF DRAWINGS: 46 INVENTOR(S):
PATENT ASSIGNEE(S): PRIMARY EXAMINER: ASSISTANT EXAMINER: PATENT INFORMATION: APPLICATION INFO.: DOCUMENT TYPE: L5 ANSWER 11 OF ACCESSION NUMBER: TITLE: PRIMARY EXAMINER FILE SEGMENT:

Peterson, Per A., La Jolla, CA, United States Jackson, Michael, Del Mar, CA, United States Langlade-Demoyen, Pierre, Del Mar, CA, United States The Scripps Research Institute, La Jolla, CA, United States (U.S. corporation) PATENT ASSIGNEE(S)

US 5827737
US 1996-66685
Continuation of Ser. No. US 1994-2097, filed on 10
Rar 1994, now patented, Pat. No. US 525991 which is a continuation of Ser. No. US 1992-841662, filed on 19
Reb 1992, now patented, Pat. No. US 532991 which is a continuation of Ser. No. US 1992-841662, filed on 19
Utility
Granted
Tasng, Cecila J.
VanderVegt, F. Pierre
Townsend & Townsend & Crew DATE KIND NUMBER ASSISTANT EXAMINER: LEGAL REPRESENTATIVE: NUMBER OF CLAIMS: EXEMPLARY CLAIM: NUMBER OF DRAWINGS: APPLICATION INFO.: RELATED APPLN. INFO.: PATENT INFORMATION: DOCUMENT TYPE: FILE SEGMENT: PRIMARY EXAMINER:

25 Drawing Figure(s); 19 Drawing Page(s)

LINE COURT:

AB The present invention relates to a rational, elegant means of producing, the present invention relates to a rational, elegant means of producing, and using Class I molecules to specifically activate CDB cells in vitro, and their therapeutic applications in the treatment of a variety of conditions, including cancer, tunors or neoplasias, as well as viral, retroviral, autoimmune, and autoimmune-type diseases. The present invention also relates to vectors, cell lines, recombinant DNA molecules encoding human .beta.2 microglobulin or Class I MHC molecules in soluble and insoluble form, and methods of producing same.

USPATFULL
1998-11913 USPATFULL
PERCECTIVE 17 KDA malaria hepatic and erythrocytic
stage immunogen and gene LS ANSWER 13 OF 46 ACCESSION NUMBER: INVENTOR (S):

Hoffman, Stephen L., Gaithersburg, MD, United States Charcoenvir, Yugin, Silver Spring, MD, United States Hedstrom, Richard C., Gaithersburg, MD, United States Doolan, Denise L., Rockville, MD, United States Doolan, Denise L., Rockville, MD, United States Colon Secretary of the Navy, Washington, DC, United States (U.S. government) PATENT ASSIGNEE(S):

17 Drawing Figure(s); 7 Drawing Page(s) (8) 19980929 DATE KIND Cunningham, Thomas M. Spevack, A. David US 5814617 US 1994-319704 Utility Granted NUMBER 1590 FILE SEGMENT:
PRIMARY EXAMINER:
LEGAL REPRESENTATIVE:
NUMBER OF CLAIMS:
EXEMPLARY CLAIM:
NUMBER OF DRAMINGS: PATENT INFORMATION: APPLICATION INFO.: DOCUMENT TYPE: LINE COUNT:

An Igg1 monoclonal antibody, Navy Yoelii Liver Stage 3 (NYLS3) does not recognize sporozoites, but recognizes P. yoelii liver stage parasites within 6 hours of invasion of mouse hepatocytes, and throughout the hepatic and asexual erythrocytic stages of the life cycle. When added to primary cultures of mouse hepatocytes 24 hours after incoulation with P. yoelii sporozoites, when all sporozoites have invaded hepatocytes, NYLS3 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An IGG1 monoclonal antibody. Navy Y.

Will all minates up to 98% of liver stage parasites. Intravenous injection of NYLS3 into mice delays the onset and reduces the density of blood stage parasitemia after sporozoite or blood stage challenge. The protein recognized by this mab is identified and designated P. yoelil hepatic and erythrocytic stage protein. They are PyHED1. The gene encoding PyHED17 and a DNA vaccine comprising exons of the DNA that encodes PyHED17 are disclosed. A DNA vaccine consisting of exon 1 and part of exon 2 of the gene encoding PyHED17 protects 86% of A/J mice, 33% and development of blood-stage parasitemia. A combination of DNA vaccines complete protection against development of blood-stage parasitemia. A combination of DNA vaccines complete protection against development of blood-stage parasitemia in BALB5 c mice and 71% protection may be additive. Combinations of other malaria antigens are covered. The application discloses the P. falciparum homotogo of PyHED17 and included protection may be additive. Combinations of other falciparum homotogo of PyHED17 and includes the means of identification of the PyHED17 homologs of the other Plasmodium species which infect humans, specifically P. vivax, P. ovale and P. malariae.

Heat shock-like protein
Hilman, Jennifer L., San Jose, CA, United States
Shah, Purvi, Sunnyvale, CA, United States
CHOYEP Pharmaceuticals, Inc., Palo Alto, CA, United
States (U.S. corporation) 5 Drawing Figure(s); 4 Drawing Page(s) 8 19980929 DATE KIND Wax, Robert A. Bugalsky, Gabriele E. Billings, Lucy J. US 5814481 US 1997-846134 Utility NUMBER USPATFULL Granted ASSISTANT EXAMINER: LEGAL REPRESENTATIVE: NUMBER OF CLAIMS: 46 EXEMPLARY CLAIM: NUMBER OF DRAWINGS: PATENT ASSIGNEE(S): PATENT INFORMATION: APPLICATION INFO.: DOCUMENT TYPE: LS ANSWER 14 OF ACCESSION NUMBER: PRIMARY EXAMINER: FILE SEGMENT: INVENTOR (S):

LINE COUNT:

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

CAS INDEXING THE present invention provides a novel heat shock-like protein (HSPRO) and polynucleotides which identify and encode HSPRO. The invention also provides expression vectors, host cells, agonists, antibodies, and antagonists. The invention also provides methods for treating disorders associated with expression of HSPRO.

Inhibitors of IMPDH enzyme
Armistead, David M., Maymard, MA, United States
Badia, Michael C., Bedford, MA, United States
Bedia, Michael C., Alliston, MA, United States
Beniel, Randy S., Alliston, MA, United States
Bethiel, Randy S., Alliston, MA, United States
Frank, Catharine A., Marlborough, MA, United States
Novak, Perry M., Milford, MA, United States
Ronkin, Steven M., Matertown, MA, United States
Saunders, Jeffrey O., Acton, MA, United States
Vertex Pharmaceuticals Incorporated, Cambridge, MA,
United States (U.S. corporation) LS ANSWER 15 OF 46 USPATFULL ACCESSION NUMBER: 1998:11 PATENT ASSIGNEE(S): INVENTOR (S):

NUMBER US 5807876 PATENT INFORMATION:

Shah, Mukund J. Kifle, Bruck Fish & Neave, Haley, Jr., James F., Govindaswamy, N. PRIMARY EXAMINER: STAILED
ASSISTANT EXAMINER: STAB, Wukund J.
ASSISTANT EXAMINER: Kifle, Bruck
LEGAL REPRESENTATIVE: Fish & Neave, Haley,
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIMS: 1
LINE COUNT: 1
A94
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a now US 1996-636361 Utility Granted APPLICATION INFO.: DOCUMENT TYPE: SEGMENT:

The present invention relates to a novel class of compounds which are IMPDH inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting IMPDH enzyme activity and consequently, may be advantageously used as agents for immunosuppression. This invention also relates to methods for inhibiting the activity of IMPDH using the compounds of this invention and related compounds.

1998:101540 USPATFULL Human protein disulfide isomerase Braxcon, Scott Michael, San Mateo, CA, United States Murry, Lynn E., Portola Valley, CA, United States Incyte Pharmaceuticals, Inc., Palo Alto, CA, United States (U.S. corporation) USPATFULL LS ANSWER 16 OF 46 ACCESSION NUMBER: PATENT ASSIGNEE (S): INVENTOR (S):

US 5798249
US 1996-650275
US 1996-650275
19960516 (8)
Continuation-in-part of Ser. No. US 1996-649740, filed
on 15 May 1996
Utility DATE KIND NUMBER APPLICATION INFO.: RELATED APPLN. INFO.: PATENT INFORMATION:

13 Drawing Figure(s); 13 Drawing Page(s) DOCUMENT TYPE:
Outlity
FILE SEGMENT:
FILE SEGMENT:
GRAINE GRAINER:
ASSISTANT EXAMINER:
LEGAL REPRESENTATIVE:
Billings, Lucy J.
NUMBER OF CLAIMS:
EXEMPLARY CLAIM:
NUMBER OF DRAWINGS:
LINE COUNT:
LINE COUNT:
AS INDEXING IS AVAILABLE FOR THIS PATENT.
AB THE present invention provides a polyw

The present invention provides a polynucleotide (pdih) the partial sequence for which was initially isolated from a lung cDNA library and which identifies and encodes a novel human protein disulfide isonerase (PDIH). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding PDIH. The invention also provides for the use of purified PDIH and its agonists in the commercial production of recombinant proteins and in pharmaceutical compositions for the treatment of diseases associated with the abnormal expression of PDIH. Additionally, the invention provides for the use of antisense molecules to pdih or inhibitors of PDIH in pharmaceutical compositions for treatment of diseases resulting secretion of PDIH. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, fragments or the complement thereof, which hybridize with the genomic sequence or the complement thereof, which hybridize with the genomic sequence or the complement thereof, and anti-PDIH antibodies which specifically bind the transcribed and anti-PDIH antibodies which specifically bind to the polypeptide, PDIH.

USPATFULL

1998:92162 USPATFULL
Vertebrate embryonic pattern-inducing proteins and uses related thereto L5 ANSWER 17 OF 46 ACCESSION NUMBER: TITLE:

Granted Walsh, Stephen Sorensen, Kenneth A. Vincent, Matthew P., Arnold, Beth E.Foley, Hoag & Eliot The present invention concerns the discovery that proteins encoded by a family of vertebrate genes, termed here hedgehog-related genes, comprise morphogenic signals produced by embryonic patterning centers, and are involved in the formation of ordered spatial arrangements of differentiated tissues in vertebrates. The present invention makes available compositions and methods that can be utilized, for example to generate and/or maintain an array of different vertebrate tissue both in 1998:91811 USPATFULL between that has experienced elevated teneration of wheat that has experienced elevated temperatures during the grain filling period Bernardin, John E., El Sobrante, CA, United States The United States of America as represented by the Secretary of Agriculture, Washington, DC, United States (U.S. corporation) US 5789180 19980804 183 19981013 (8) Continuation of Ser. No. US 1994-192873, filed on 7 Feb 1994, now abandoned Grun, James L. Silverstein, M. Howard, Fado, John D., Connor, Margaret Ingham, Philip W., Summertown, England McMahon, Andrew P., Lexington, MA, United States Tabin, Clifford J., Cambridge, MA, United States Resident and Fellows of Harvard College, Cambridge, MA, United States (U.S. corporation) 1 12 Drawing Figure(s); 15 Drawing Page(s) 19980804 DATE DATE KIND LINE COUNT:

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention concerns the Hutzell, Paula K. US 5789543 US 1993-176427 NUMBER NUMBER Utility LS ANSWER 18 OF 46 USPATFULL ACCESSION NUMBER: 1998:918 Granted vitro and in vivo. PATENT INFORMATION: APPLICATION INFO.: RELATED APPLN. INFO.: PRIMARY EXAMINER: ASSISTANT EXAMINER: LEGAL REPRESENTATIVE: ASSISTANT EXAMINER: LEGAL REPRESENTATIVE: EXEMPLARY CLAIM: NUMBER OF DRAWINGS: INVENTOR(S):
PATENT ASSIGNEE(S): PATENT ASSIGNEE(S): PATENT INFORMATION: APPLICATION INFO.: NUMBER OF CLAIMS: FILE SEGMENT: PRIMARY EXAMINER: DOCUMENT TYPE: DOCUMENT TYPE: FILE SEGMENT: INVENTOR (S):

1,8 6 Drawing Figure(8); 6 Drawing Page(s) NUMBER OF CLAIMS: EXEMPLARY CLAIM: NUMBER OF DRAWINGS:

wheat grain or flour is measured, and the level is compared to a calibration curve that correlates the level of wheat heat stress peptid

calibration curve that co and the end-use property.	calibration curve that correlates the level of wheat heat stress peptide and the end-use property.	NUMBER OF DRAWINGS: LINE COUNT:
L5 ANSWER 19 OF 46 1 ACCESSION NUMBER: TITLE:	USPATFULL 1998:88652 USPATFULL Therapeutic and diagnostic methods and compositions	CAS INDEXING IS AVA AB A 65 KD heat antibodies t in humans th
INVENTOR (S):	based on notch proteins and nucleic acids Artavanis-Taskonas, Spyridon, Hamden, CT, United States Fehon, Richard Grant, Durham, NC, United States Zagouras, Panayiotis, New Haven, CT, United States Blaumueller, Christine Marie, New Haven, CT, United	a process le hsp65 can be hsp65 molecu cross-reacti: can be used
PATENT ASSIGNEE(S):	States Yale University, New Haven, CT, United States (U.S. corporation)	of clinical receptor pep IDDM.
PATENT INFORMATION: APPLICATION INFO.: RELATED APPLN. INFO.:	NUMBER KIND DATE 195080728 195080728 US 1993-83590 19930625 (8) Continuation-in-part of Ser. No. US 1992-955012, filed on 30 Sep 1992, now abandoned And a continuation-in-part of Ser. No. US 1992-879038, filed	=> d 20-30 ibib ab L5 ANSWER 20 OF 4 ACCESSION NUMBER: TITLE:
DOCUMENT TYPE: FILE SEGMENT: PRIMARY EXAMINER: LEGAL REPRESENTATIVE: NUMBER OF CLAIMS: EXEMPLARY CLAIMS:	Utility Granted Scheiner, Toni R. Pennie & Edmonds LLP 9	INVENIOR(5): PATENT ASSIGNEE(S):
NUMBER OF DRAWINGS: 70 Drawing Figure LINE COUNT: 4658 CAS INDEXING IS AVAILABLE FOR THIS PATENT AB The present invention relates to detection of malignancy or nervous of Notch proteins or nucleic acids inhibiting Notch expression are all	OF DRAWINGS:  4658  4658  WUNT: 4658  ANAILABLE FOR THIS PATENT.  The present invention relates to diagnostic methods and compositions for detection of malignancy or nervous system discrders based on the level of Notch proteins or nucleic acids. Therapeutic methods and methods of inhibiting Notch expression are also provided.	PATENT INFORMATION: APPLICATION INFO.: RELATED APPLN. INFO
LS ANSWER 20 OF 46 the CCESSION NUMBER: TITLE: INVENTOR(S): PATENT ASSIGNEE(S):	USPATEUL. 1998.82145 USPATFULL Diagnosis and treatment of insulin dependent diabetes mellitus using heat shock protein determinents Cohen, Irun R., Rehovot, Israel Blias, Dana, Rehovot, Israel Markovits, Doron, Rehovot, Israel Yeda Research and Development Co. Ltd., Rehovot, Israel	DOCUMENT TYPE: FILE SEGMENT: PRIMARY EXAMINER: LEGAL REPRESENTATIV NUMBER OF CLAIMS: EXEMPLARY CLAIMS:
PATENT INFORMATION: APPLICATION INFO.: RELATED APPLN. INFO.:	NUMBER KIND DATE  NUMBER KIND DATE  US 5780034 US 1995-384454 US 1996-433127, filed on 14 Mar 1990, now abandoned which is a continuation of Ser. No. US 1990-433127, filed on 14 Mar 1990, now abandoned which is a continuation-in-part of Ser. No. US	NUMBER OF DRAWINGS: LINE COUNT: CAS INDEXING IS AVA AB A 65 KD heat A mutibodies ti in humans the a process lee hsp65 can be hsp65 can be hsp65 can be
DOCUMENT TYPE: FILE SEGMENT: PRIMARY EXAMINER: LEGAL REPRESENTATIVE: NUMBER OF CLAIMS:	1895-3/14844 which is a continuation-in-part of Ser. No. US 5114844 which is a continuation-in-part of Ser. No. US 1989-322864, filed on 14 Mar 1989, now abandoned Utility Granted Cunningham, Thomas M. Browdy and Neimark	can be used of clinical in call receptor pept IDDM.  LS ANSWER 21 OF 41 ACCESSION NUMBER:

```
US 578004

US 1995-38444

US 1995-384454

Continuation of Ser. No. US 1992-937449, filed on 31

Aug 1995. now abandoned which is a continuation of Ser.

No. US 1990-493127, filed on 14 Mar 1990, now abandoned

which is a continuation-in-part of Ser. No. US

1989-371249, filed on 26 Jun 1989, now patented, Pat.

No. US 5114844 which is a continuation-in-part of Ser.

No. US 5114844 which is a continuation-in-part of Ser.

Utility

Granted

Cunningham, Thomas M.
                                                                                                                                                             LINE COUNT.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A 65 KD heat shock protein, proteins cross-reactive therewith, antibodies therefor or Tealls specific therefor can be used for detecting in humans the existence of, a tendency to develop, or the initiation of a process leading to insulin dependent diabetes mellitus. Antibodies to hap65 some be used to detect the hap65 molecule in blood or unine. The hap65 molecule of any species, or any other substance immunologically cross-reactive therewith, when administered with a tolerogenic carrier, can be used for the prevention or treatment of IDDM prior to development of clinical symptoms thereof. T cells, active fragments thereof or the receptor peptide thereof can also be used for prevention or treatment of
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        A 65 KD heat shock protein, proteins cross-reactive therewith, and food manithodies therefor or T cells specific thereto can be used for detecting in humans the existence of, a tendency to develop, or the initiation of a process leading to insulin dependent diabetes mellitus. Antibodies to hisp65 can be used to detect the hisp65 molecule in blood or urine. The hisp65 molecule of any species, or any other substance immunologically cross-reactive therewith, when administered with a tolerogenic carrier, of an be used for the prevention or treatment of IDDM sprior to development of clinical symptoms thereof. T cells, active fragments thereof or the receptor peptide thereof can also be used for prevention or treatment of
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Diagnosis and treatment of insulin dependent diabetes mealitus using heat shock protein determinents Cohen, Trun R., Rehovot, Israel Elias, Dana, Rehovot, Israel Markovite, Dozon, Rehovot, Israel Yeda Research and Development Co. Ltd., Rehovot, Israel (non-U.S. corporation)
                                                                           Drawing Figure(s); 6 Drawing Page(s)
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   8 Drawing Figure(s); 6 Drawing Page(s)
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    DATE
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             KIND
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 USPATFULL
1998:82345 USPATFULL
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          PRIMARY EXAMINER: Cunningham, Thomas M LEGAL REPRESENTATIVE: Browdy and Neimark NUMBER OF CLAIMS: 18 EXEMPLARY CLAIM: 1 NUMBER OF DRAWINGS: 8 Drawing Figure(8): LING COUNT: 1667
CAS INDEXING IS AVAILABLE FOR THIS PATENT. AB A 65 KD heat shock proteins of the county of
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             NUMBER
                                                                                                                                  1667
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           PATENT INFORMATION:
APPLICATION INFO.:
RELATED APPLN. INFO.:
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   LS ANSWER 20 OF 46
ACCESSION NUMBER:
EXEMPLARY CLAIM:
NUMBER OF DRAWINGS:
LINE COUNT:
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           PATENT ASSIGNEE(S):
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     => d 20-30 ibib ab
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       DOCUMENT TYPE:
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        INVENTOR (S):
```

USPATFULL 1998:78722 USPATFULL Recombinant mycobacterial vaccines

46

Inventor(s):	O'Donnell, Michael A., Sudbury, MA, United States Duda, Rosemary B., Carlisle, MA, United States
PATENT ASSIGNEE(S):	DeWolf, William C., Southborough, MA, United States Aldovini, Anna, Winchester, MA, United States Young, Richard A., Winchester, MA, United States Beth Israel Hospital Association, Boston, MA, United States (U.S. corporation) Whitchead Institute for Biomedical Research, Cambridge, MA, United States (U.S. corporation)
PATENT INFORMATION: APPLICATION INFO.: RELATED APPLN. INFO.:	US 577465 19980007 19980007 19954665 19980007 19950605 (8) Continuation of Ser. No. US 1993-96027, filed on 22 Jul 1993, now patented, Pat. No. US 5591632 which is a continuation-in-part of Ser. No. US 1991-711334, filed on 6 Jun 1991, now abandoned which is a continuation-in-part of Ser. No. US 1989-367894, filed
	On 19 Jun 1999, mow abandoned And Ser. No. US 1989-361944, filed on 5 Jun 1989, now patented, Pat. No. US 5504005 which is a continuation-in-part of Ser. No. US 1988-223089, filed on 22 Jul 1988, now abandoned And Ser. No. US 1988-216390, filed on 7 Jul 1988, now abandoned which is a continuation-in-part of Ser. No. US 1988-16346, filed on 3 Mar 1988, now abandoned which is a continuation-in-part of Ser. No. US 1987-20451, filed on 2 Mar 1987, said Ser. No. US -223089 which is a continuation-in-part of Ser. No. US
DOCUMENT TYPE: FILE SEGMENT: PRIMARY EXAMINER: ASSISTANT EXAMINER: LEGAL REPRESENTATIVE: NUMBER OF CLAIMS: EXEMPLARY CLAIM: WUMBER OF DRAWINGS:	
LINE COUNT:  CAS INDEXING IS AVAILABLE FOR THIS PATENT AB The present invention relates to recombinant M. bovis BCG, which expredient or polypeptide (e.g., an antigen) again desired, or a cytokine.	BAXING IS AVAILABLE FOR THIS PATENT.  EXING INVENTION TELETES TO recombinant mycobacteria, particularly recombinant M. bovis BCG, which express heterologous DNA encoding a product (protein or polypeptide) of interest, such a protein or polypeptide (e.g., an antigen) against which an immune response is desired, or a cytokine
LS ANSWER 22 OF 46 L ACCESSION NUMBER: TITLE:	USPATFUL. 1998:72255 USPATFULL Recombinant poxviruses with foreign DNA in essential regions
INVENTOR(S): PATENT ASSIGNEE(S):	Falker, Falko-Gunter, Vienna, Austria Holzer, Georg, Vienna, Austria Dorner, Friedrich, Vienna, Austria Immuno Aktiengesellschaft, Vienna, Austria (non-U.S.
PATENT INFORMATION: APPLICATION INFO.: RELATED APPLN. INFO.: DOCUMENT TYPE:	NUMBER KIND DATE US 5770212 US 1997-802985 US 1997-802985 US 1997-802985 US 1997-802985 US 1997-802985 US 1996-816133, filed on 14 Mar 1996 which is a continuation-in-part of Ser. No. US 1994-235992, filed on 29 Apr 1994, now abandoned Utility

```
FILE SEGMENT:
Granted
FILE SEGMENT:
Granted
FILE SEGMENT:
Campell, Bruce R.
LEGAL REPRESENTATIVE:
Foley & Lardner
NUMBER OF CLAIMS:
A4
A4
A5 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT:
AND DEALINES:
AB Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT:
AND DEFECTIVE POXYLINES FOR THIS PATENT.
AB Defective poxyliuses that lack a function imparted by an essential arcination of its parental poxylius are provided for protein production and vaccination. A DNA polymolectide encoding a protein is inserted into the defective poxylius and placed under transcriptional control of a promocer. The defective poxylius is viable when the lost function of the essential region is complemented by a host cell, transgenic animal or
                       PRIMERY EXAMINER:

DEGAL PRERESENTATIVE:

NUMBER OF CLAIM:

1

NUMBER OF DRAWINGS:

1266

AS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Defective poxvirues that lack a function imparted by an essential region of its parental poxvirus are provided for protein production and vaccination. A DNA polymoclectide encoding a protein production and vaccination. A DNA polymoclectide encoding a protein is inserted into the defective poxvirus and placed under transcriptional control of a promoter. The defective poxvirus is viable when the lost function of the essential region is complemented by a host cell, transgenic animal or helper virus.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      US 576882

US 1996-61613 1996016

US 1996-61613 1996014 (8)

Continuation-in-part of Ser. No. US 1994-235392, filed

on 29 Apr 1994, now abandoned

Utility Granted

Campell, Bruce R.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        1998-19767 USPATFULL.
Cell stress transcriptional factors
Wu, Carl, Bethesda, MD, United States
Clos, Joachim, Bethesda, MD, United States
Restwood, J. Timothy, Rockville, MD, United States
Rabindran, Sridhar, Silver Spring, MD, United States
The United States of America as represented by the
Department of Health and Human Services, Washington,
DC, United States (U.S. government)
                                                                                                                                                                                                                                                                                                                                                                                                                                                                       L5 ANSWER 23 OF 46 USPATFULL
ACCESSION NUMBER: 1998:68807 USPATFULL
TITLE: recombinant poxviruses with foreign DNA in essential
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Holzer, Georg, Vienna, Austria
Dorner, Friedrich, Vienna, Austria
Immno Aktiengesellschaft, Vienna, Austria (non-U.S.
corporation)
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          regions
Falkner, Falko-Gunter, Vienna, Austria
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    8
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               19980526
19940107
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            KIND DATE
Granted
Mosher, Mary E.
Foley & Lardner
19
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              US 5756343
US 1994-178477
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            NUMBER
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             NUMBER
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              LS ANSWER 24 OF 46 USPATFULL ACCESSION NUMBER: 1998:577
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              PATENT INFORMATION:
APPLICATION INFO.:
RELATED APPLN. INFO.:
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  PATENT ASSIGNEE(S):
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  PATENT INFORMATION:
APPLICATION INFO.:
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      PATENT ASSIGNEE(S):
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        DOCUMENT TYPE:
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        INVENTOR(S):
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              INVENTOR (S):
```

Division of Ser. No. US 1990-617910, filed on 26 1990, now abandoned 44 Drawing Figure(s); 28 Drawing Page(s) Low, Christopher S. F. Morgan & Finnegan, L.L.P. LINE COUNT:

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to DM 1990, no Utility LEGAL REPRESENTATIVE: NUMBER OF CLAIMS: EXEMPLARY CLAIM: NUMBER OF DRAWINGS: RELATED APPLN. INFO.: PRIMARY EXAMINER:

The present invention relates to DNA sequence coding for part or all of the heat shock transcription factor or heat shock factor (HSF) proteins derived from humans and Drosophila, and the proteins encoded by these sednences

The present invention also includes methods for detecting HSF in a biological sample. The presence of HSF in the nucleus of a cell can be detected with specific anti-HSF antibody reagents. The presence of such HSF proteins in the nucleus indicates a stressed condition including diseases. Furthermore, the presence of multimeric HSF in the crude or fractionated cell extract is indicative of a stressed state.

USPATFULL 1998:51728 USPATFULL 46 LS ANSWER 25 OF ACCESSION NUMBER: INVENTOR (S):

Deltex proteins

Artavania-Taakonas, Spyridon, Hamden, CT, United States
Busseau, Isabelle, Bures-Sur-Yvette, France
Diederich, Robert J., New Haven, CT, United States
Matsumo, Kenji, New Haven, CT, United States
Yale University, New Haven, CT, United States
Yale University, New Haven, CT, United States corporation) PATENT ASSIGNEE(S):

58 Drawing Figure(s); 40 Drawing Page(s) (8) 19980512 19940121 DATE KIND FILE SEGNENT: Granted
ASISTAMT EXAMINER: Walsh, Stephen
ASSISTAMT EXAMINER: Sorensen, Kenneth A.
LEGAL REPRESENTATIVE: Pennie & Edmonds Lip
KWUMER OF CLAIMS: 1
NUMBER OF DRAWINGS: 58 Drawing Figure(s);
LINE COUNT: 4194
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to amino Walsh, Stephen Sorensen, Kenneth A. Pennie & Edmonds LLP US 5750652 US 1994-185432 Utility Granted NUMBER PATENT INFORMATION: APPLICATION INFO.: DOCUMENT TYPE:

The present invention relates to amino acid sequences of the encoded deltex protein. The invention further relates to fragments and other derivatives, and analogs, of deltex proteins. In specific embodiments, the invention relates to deltex protein derivatives and analogs of the invention which are functionally active, or which comprise one or more domains of a deltex protein, including but not limited to the Gil-rich clusters, SH3 binding domains which mediate binding to Notch or repeats, domains which mediate binding to Notch or repeats, domains which mediate binding to Notch or repeats, domains which mediate binding to a second deltex protein, or any combination of the foregoing. The present invention also relates to compositions based on deltex proteins.

USPATFULL LS ANSWER 26 OF 46 ACCESSION NUMBER: TITLE:

1998:51204 USPATFULL Immunocherapeutic stress protein-peptide complexes adinst cancer

LINE COUNT:

CAS INDEXING I SAVAILABLE FOR THIS PATENT.

AB Disclosed is a method for inhibiting the proliferation of a tumor in a mammal. The method involves the steps of (a) isolating a stress protein-peptide complex from tumor cells previously removed from the protein-peptide complex from tumor cells previously removed from the mammal and (b) administering the isolated stress protein-peptide complex back to the mammal in order to stimulate in the mammal an immune response against the tumor from which the complex was isolated. Stress protein-peptide complexes having particular utility in the practice of the instant invention include the Hsp70-peptide, Hsp90-peptide and gp96-peptide complexes. US 5750119 19980512 US 1994-315892 19940930 (8) Continuation-in-part of Ser. No. US 1994-180685, filed Utility Srivastava, Pramod K., Riverdale, NY, United States Mount Sinai School of Medicine Of The City University of New York, New York, NY, United States (U.S. DATE KIND Feisee, Lila Bansal, Geetha P. Pennie & Edmonds LLP corporation) NUMBER ASSISTANT EXAMINER: LEGAL REPRESENTATIVE: NUMBER OF CLAIMS: EXEMPLARY CLAIM: RELATED APPLN. INFO.: PATENT ASSIGNEE(S): PATENT INFORMATION: INFO. PRIMARY EXAMINER: DOCUMENT TYPE: SEGMENT: INVENTOR (S): APPLICATION

1998:48564 USPATFULL PSJAS protein and antibody therefor Kuless-Martin, Molly F. Buffalo, NY, United States Health Research, Inc., Buffalo, NY, United States (U. corporation) USPATFULL ANSWER 27 OF 46 INVENTOR(S): PATENT ASSIGNEE(S): L5 ANSWER 27 OF ACCESSION NUMBER:

US 5747650 19980505 US 1996-644456 19960510 (8) Continuation-in-part of Ser. No. US 1993-100496, filed On 2 Aug 1993 Utility DATE KIND NUMBER APPLICATION INFO.: RELATED APPLN. INFO.: PATENT INFORMATION:

Granted Scheiner, Toni R. Bansal, Geetha P. Dunn, Michael L. DOCUMENT TYPE: FILE SEGMENT:

PRIMARY EXAMINE: Scheiner, Toni R. ASSISTANT EXAMINE: Scheiner, Toni R. ASSISTANT EXAMINE: Bansal, Geetha P. LEGAL REPRESENTATIVE: Dunn, Michael L. LEGAL REPRESENTATIVE: Dunn, Michael L. LEGAL REPRESENTATIVE: 1

NUMBER OF CLAINS: 1

EXEMPLARY CLAINS: 26 Drawing Figure(8); 11 Drawing Page(8)

LINE COUNT: 2 ANAILABLE FOR THIS PATENT.

AB In accordance with the present invention, we have discovered and purified a protein designated herein as p53as, which protein is present in normal cells of a mammal and is essentially identical to known normal growth controlling protein p53 of the same mammal, at least until the final 50 amino acids of the carboxy terminal and of the protein. The invention further includes an antibody specific for protein p53as, which antibody is designated herein as Ab p53as. The antibody may be either a monoclonal or polyclonal antibody and may be specific for p53as of any particular mammal such as mice and humans.

ANSWER 28 OF 46 USPATFULL 5

1998:36577 USPATFULL.
Vectors and prokaryotes which autocatalytically delete annibiotic resistance
Haun, Shirley L., Gaithersburg, MD, United States
Stover, Charles K., Mercer Island, WA, United States
Harfull, Graham, Pitrsburgh, PA, United States
Hanson, Mark S., Columbia, MD, United States
Jacobs, William R., City Island, NY, United States
Medimmune, Inc., Gaithersburg, MD, United States
corporation) A diagnostic test, and a device for conducting the test, for assessing whether patient chest pain is cardiac in origin and for differentiating between unstable angina and myocardial infarction as a cause of patient chest pain is described. The diagnostic test comprises simultaneously detecting at least three selected cardiac markers with the use of at least three different monoclonal or polyclonal antibody pairs, each member of which is complementary to a different marker, which is released by heart muscle at varying stages after the onset of chest pain and is indicative of the cause of the chest pain. US 5744358

US 5744358

US 5746354

US 57960905 (8)

Continuation of Ser. No. US 1995-420298, filled on 11

Apr 1995, now patented, Pat. No. US 564016 which is a continuation-in-part of Ser. No. US 1993-26453, filled on 3 Mar 1993, now abandoned which is a continuation-in-part of Ser. No. US 1991-695381, filled on 3 May 1991, now patented, Pat. No. US 5290678, issued on 1 Mar 1994 19950420 (8) Ser. No. US 1992-861002, filed 1998:45097 USPATFULL
method and device for diagnosing and distinguishing
method and device for diagnosing and distinguishing
check pain in early onset thereof
Jackowski, George, Inglewood, Canada
Spectral biagnostics Inc., Toronto, Canada (non-U.S.
corpozation) 16 Drawing Figure(s); 10 Drawing Page(s) Fleisher, Mindy Welss, Bonnie D. Herron, Charles J., Olstein, Elliot M. 19980407 DATE 19901012 DATE US 5736367 19 US 1995-425380 19 Continuation-in-part of Se on 31 Mar 1992 Utility KIND KIND PRIMERY EXAMINER: Wolski, Susan LEGAL REPRESENTATIVE: Klauber & Jackson Number OF CLAIMS: 13 EXEMPLARY CLAIM: 1 NUMBER OF DRAWINGS: 16 Drawing Figure(s); LINE COUNT: 2336

CAS INDEXIS IS AVAILABLE FOR THIS PATENT. AB A diagnostic test, and a device for co CA 1990-2027434 NUMBER NUMBER NUMBER USPATFULL PATENT INFORMATION: APPLICATION INFO.: RELATED APPLN. INFO.: PRIORITY INFORMATION: DOCUMENT TYPE: FILE SEGMENT: PATENT INFORMATION: APPLICATION INFO.: RELATED APPLN. INFO.: PRIMARY EXAMINER: ASSISTANT EXAMINER: LEGAL REPRESENTATIVE: LS ANSWER 29 OF 46
ACCESSION NUMBER: PATENT ASSIGNEE(S): PATENT ASSIGNEE(S): ACCESSION NUMBER: DOCUMENT TYPE: INVENTOR (S): FILE SEGMENT: INVENTOR (S):

The invention relates to conjugates of poorly immunogenic antigens, e.g. peptides, proteins and polysaccharides, with a synthetic peptide carrier constituting a reall epitope derived from the sequence of human heat shock protein hap65, or an analog thereof, said peptide or analog being capable of increasing substantially the immunogenicity of the poorly immunogenic antigen. Suitable peptides according to the invention are Pep278H, which corresponds to positions 439-448 of human hap65, and Pep II, which corresponds to positions 437-448 of human hap65, but in which two cysteine residues at positions 442 and 447 are replaced serine Conjugates of poorly immunogenic antigens and synthetic peptide carriers and vaccines comprising them Cohen, Irun R., Rehovot, Israel Pridkin, Matityahu, Rehovot, Israel Konen-Waisman, Stephanie, Tel Aviv, Israel Yeda Research and Development Co. Ltd., Israel (non-U.S. corporation) LINE COUNT:

CAS INDEXING S AVAILABLE FOR THIS PATENT.

AB A vector and a prokaryote transformed therewith which includes nucleic muclectide sequences which make possible the autocatalytic deletion of nucleotide sequences encoding an antibitotic resistance phenotype. The prokaryote can be a bacterium, and in particular a mycobacterium. Such transformed mycobacteria may be employed in vaccines, thereby eliminating the autendant risk of vaccines including antibiotic resistance markers. PCT 371 date PCT 102(e) date 14 1 42 Drawing Figure(s); 39 Drawing Page(s) 49 Drawing Figure(s); 19 Drawing Page(s) 8 19940217 19950222 19930728 19950222 19980407 DATE 19920730 DATE KIND USPATFULL 1998:36365 USPATFULL ₫. IL 1992-102687 Utility Granted Woodward, Michael P NUMBER OF CLAIMS: 25
EXEMPLARY CLAIM: 15
NUMBER OF DAMINGS: 49 Drawing Figure (6
LINE COUNT; ANJURABLE FOR THIS PATENT.
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to conjugates US 5736146 WO 9403208 US 1995-379613 WO 1993-US7096 NUMBER NUMBER PRIORITY INFORMATION: DOCUMENT TYPE: 46 LEGAL REPRESENTATIVE: NUMBER OF CLAIMS: EXEMPLARY CLAIM: NUMBER OF DRAWINGS: PATENT ASSIGNEE(S): PATENT INFORMATION: APPLICATION INFO.: LS ANSWER 30 OF ACCESSION NUMBER: PRIMARY EXAMINER: FILE SEGMENT: INVENTOR (S):

Conjugates of poorly immunogenic antigens and synthetic peptide carriers and vaccines comprising them Cohen, Irun R., Rehovot, Israel Fridkin, Matityahu, Rehovot, Israel

USPATFULL 1998:36365 USPATFULL

ANSWER 30 OF 46

L5 ANSWER 30 OF ACCESSION NUMBER:

INVENTOR (S):

=> d 30-46 ibib ab

PCT 371 date PCT 102(e) date Konen-Waisman, Stephanie, Tel Aviv, Israel Yeda Research and Development Co. Ltd., Israel (non-U.S. corporation) 19950222 19980407 19940217 19930728 DATE 19920730 DATE KIND ď Woodward, Michael Pennie & Edmonds US 5736146 WO 9403208 US 1995-379613 WO 1993-US7096 IL 1992-102687 Utility NUMBER NUMBER Granted PATENT ASSIGNEE (S): PATENT INFORMATION: APPLICATION INFO.:

49 Drawing Figure(s); 19 Drawing Page(s) LEGAL REPRESENTATIVE: Pennie & Edmonds NUMBER OF CLAIMS: 25 LES EE EMONDS IN INDIANCE OF CLAIMS: 49 Drawing Figure (LINE COUNT: 1401

CAS INDEXING IS AVAILABLE FOR THIS PATENT: AB The invention relates to conjugates PRIORITY INFORMATION: DOCUMENT TYPE: FILE SEGMENT: PRIMARY EXAMINER:

The invention relates to conjugates of poorly immunogenic antigens, e.g. epptides, proteins and polysaccharides, with a synthetric peptide carrier constituting a T cell epitope derived from the sequence of human haat shock protein hsp65, or an analog thereof, said peptide or analog being capable of increasing substantially the immunogenicity of the poorly immunogenic antigen. Suitable peptides according to the invention are pep278h, which corresponds to positions 458-474 of human hsp65, and Peptwo, systeine residues at positions 442 and 447 are replaced serine

1998:6790 USPATFUL.
1998:6790 USPATFUL.
Immunogenic composition against Bovine Viral Diarrhea Viras II glycoprotein 53 (BVDV-II gp53)
van den Hurk, Jan, Saskatoon, Canada
Tijssen, Peter, Pointe Claire, Canada
Tijssen, Reter, Pointe Claire, Canada
Sissantoon, Canada L5 ANSWER 31 OF ACCESSION NUMBER: TITLE: INVENTOR (S):

US 5709865 US 1995-445746 19950522 (8) Continuation-in-part of Ser. No. US 1994-337618, filed On 10 Nov 1994, now abandoned Utility Knode, Marian C. Salimi, Ali R. Sholtz, Charles K.Dehlinger & Associates 13 Drawing Figure(s); 12 Drawing Page(s) 865 19980120 Granted PRIMARY EXAMINER:
ASSISTANT EXAMINER:
LEGAL REPRESENTATIVE:
NUMBER OF CLAIMS:
EXEMPLARY CLAIM:
NUMBER OF DRAMINGS: PATENT INFORMATION: APPLICATION INFO.: RELATED APPLN. INFO.: DOCUMENT TYPE: FILE SEGMENT:

DATE

KIND

NUMBER

PATENT ASSIGNEE(S):

LINE COUNT.

LINE COUNT.

LAS INDEXING IS AVAILABLE FOR THIS PATENT.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to the identification of Bovine Viral Diarrhea Virus group II (BVD-II) nucleic acid sequences (e.g., gp53 sequences) to methods of using the nucleic acid sequences for detecting BVD-II virus in animal sera, to polypeptide vital antigens derived from the

sequences and immunoreactive with sera from animals infected with Bovine Viral Datarhea group II (BVD-II) virus, to polynucleoride sequences which encode these polypeptide antigens, to an expression system capable of producing the polypeptide antigens, to vaccines containing the polypeptide antigens, to using the polypeptide antigens, to methods of using the polypeptide antigens for detecting BVD-II virus antibodies in animal sera, and to antibodies directed against these polypeptide antigens.

US 5705359
US 1995-434055
US 1991-681222, filed on S PAr 1991, now abandoned which is a continuation-in-part of Ser. No. US 1988-278386, filed on 1 Dec 1988, now abandoned And a continuation-in-part of Ser. No. US 1989-428454, filed on 27 Aug 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-428454, filed on 30 Oct 1989, now abandoned which is a continuation of Ser. No. US 1987-47736, filed on 8 May 1987, now abandoned Utility
Granted
Elliott, George C. Expression of heterologous proteins in drosophila cells oblansen, Hanne Ranch, Hojbjerg, Denmark Van Der Straten-Ponthoz, Ariane Adrienne, Chicago, IL, United States Garry, Sean M. Eagle, Alissa M., Venetianer, Stephen A., Lentz, Edward T.T. LINE COUNT:

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a method for the expression of heterologous genes, under the control of a Drosophila metallothionein promoter, inserted at high copy number into Drosophila melanogaster cells. Rosenberg, Martin, Royersford, PA, United States(4) SmithKilne Beceham Corporation, Philadelphia, PA, Inted States (U.S. corporation) DATE KIND USPATFULL 1998:1646 USPATFULL NUMBER APPLICATION INFO.: RELATED APPLN. INFO.: LS ANSWER 32 OF 46 ACCESSION NUMBER: LEGAL REPRESENTATIVE: PATENT ASSIGNEE(S): PATENT INFORMATION: FILE SEGMENT: PRIMARY EXAMINER: ASSISTANT EXAMINER: NUMBER OF CLAIMS: EXEMPLARY CLAIM: DOCUMENT TYPE: INVENTOR (S):

Expression of heterologous proteins in Drosophila cells Johansen, Hanne Ranch, Hojbjerg, Denmark Varber Straten-Ponthoz, Ariane Adrienne, Chicago, IL, United States Rosenberg, Martin, Royersford, PA, United States(4) SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation) 97:99166 USPATFULL USPATFULL ANSWER 33 OF 46 PATENT ASSIGNEE (S): ACCESSION NUMBER: INVENTOR (S):

US 5681113 19971028 US 1993-96016 1993077 (8) Continuation of Ser. No. US 1991-681222, filed on 5 Apr 1991, now abandoned which is a continuation-in-part of PATENT INFORMATION: APPLICATION INFO.: RELATED APPLN. INFO.:

KIND

NUMBER

Ser. No. US 1988-278386, filed on 1 Dec 1988, now abandoned And Ser. No. US 1990-57453, filed on 27 Aug 1990, now abandoned which is a continuation of Ser. No. US 1989-428454, filed on 30 Oct 1989, now abandoned which is a continuation of Ser. No. US 1987-47736, filed on 8 May 1987, now abandoned

Granted PRIMARY EXAMINER: LEGAL REPRESENTATIVE: SEGMENT:

Prouty, Rebecca E. Eagle, Alissa M., Lentz, Edward T., Venetianer, Stephen LINE COUNT:
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The Dresent innoction NUMBER OF CLAIMS: EXEMPLARY CLAIM:

The present invention provides a novel method for expression of high levels of heterologous proteins in Drosophila cells.

USPATFULL USPATFULL 97:59306 46 LS ANSWER 34 OF ACCESSION NUMBER:

procein

Kaye, Frederic J., Bethesda, MD, United States
Otterson, Gregory A., Columbia, MD. United States
The United States of America as represented by the
Department of Health and Human Services, Washington,
DC, United States (U.S. government) Isolation and characterization of a novel chaperone INVENTOR (S):

PATENT ASSIGNEE (S) :

19970708 DATE KIND Granted Wax, Robert A. Lau, Kawai 1994-203905 NUMBER US 5646249 US 1994-203 PATENT INFORMATION: APPLICATION INFO.: DOCUMENT TYPE: FILE SEGMENT: PRIMARY EXAMINER:

ASSISTANT EXAMINER:
Lau, Kawai
LeGAL REPRESENTATIVE:
MUMBER OF CLAIMS:
SEMPLARY CLAIM:
LINE COUNT:
AB THIS INVENTION Of the Warent STATEMY

AB THIS INVENTION Of the Warence of STCH and no Statements and protein including the corresponding gene sequence, gene fragments and protein including the corresponding gene sequence, gene fragments and protein including the corresponding gene sequence, gene fragments and protein including the corresponding gene sequence, transcripts and protein in a sample.

USPATFULL 46 Q. LS ANSWER 35 OF ACCESSION NUMBER:

97:18382 USPATFULL
Mortalin and methods for determining complementation group assignment of cancer cells
Pereira-Smith, Olivia M., Houston, TX, United States Wadhwa, Renu, Tsukuba, Japan
Baylor College of Medicine, Houston, TX, United States (U.S. corporation) PATENT ASSIGNEE(S): INVENTOR (S): TITLE:

(8 19970506

DATE

KIND

NUMBER

US 5627039 19970.
US 1994-214583 19940
Utility
Granted
Scheiner, Toni R.
Fulbright & Jaworski L.L.P. DOCUMENT TYPE: FILE SEGMENT: PRIMARY EXAMINER: LEGAL REPRESENTATIVE; PATENT INFORMATION: APPLICATION INFO.:

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The intracellular distribution of mortalin is used to determine the complementation group of tumor cells. Also disclosed are the gene sequences that encode mortalin and the amino acid sequence of the 6 1 6 Drawing Figure(8); 4 Drawing Page(s) NUMBER OF CLAIMS: EXEMPLARY CLAIM: NUMBER OF DRAWINGS: LINE COUNT:

mortalin proteins.

USPATFULL L5 ANSWER 36 OF 46 ACCESSION NUMBER: TITLE:

t

97:25972 USPATFULL
Methods and compositions for detecting and treating kidney diseases associated with adhesion of crystals thing calls
Toback, F. Gary, Chicago, IL, United States
Lieske, John C., Evanston, IL, United States
ARCH Development Corporation, Chicago, IL, United States
States (U.S. corporation) 6 Drawing Figure(s); 3 Drawing Page(s) 8 19970408 19950215 DATE Nucker, Christine M. Reeves, Julie E. Brinks Hofer Gilson & Lione KIND LINE COUNT:
CAS INDEXING IS AVAILABLE FOR THIS PATENT:
AB An autocrine crystal adhesion inhib US 5618917 US 1995-389005 Utility NUMBER ASSISTANT EXAMINER: LEGAL REPRESENTATIVE: NUMBER OF CLAIMS: EXEMPLARY CLAIM: NUMBER OF DRAWINGS: PATENT ASSIGNEE(S): PATENT INFORMATION: APPLICATION INFO.: DOCUMENT TYPE: FILE SEGMENT: PRIMARY EXAMINER INVENTOR (S):

An autocrine crystal adhesion inhibitor called CAI is an anionic, sialic acid-containing glycoprotein secreted by Kidney epithalial cells that blocks adhesion of calcium oxalate monohydrate (COM) crystals to the cell surfaces. Persons may be classified according to risk of developing Kidney stones, by measuring the amount of CAI in a biological sample. Treatment efficacy is also monitored by this method. CAI is administered in vivo to prevent nephrolithiasis. A rapid, simple assay to detect epithalial cells is characterized.

Whitehead Institute For Biomedical Research, Cambridge, MA, United States (U.S. corporation) 97:1357 USPATFULL.
Recombinant BCG
0'Donnell, Michael A., Sudbury, MA, United States
Duda. Rosemary B., Carlisle, MA, United States
Dudalf, William C., Southborough, MA, United States
Aldovini, Anna, Winchester, MA, United States
Young, Richard A., Winchester, MA, United States
Beth Israel Hospital, Boston, MA, United States corporation) USPATFULL ANSWER 37 OF 46 PATENT ASSIGNEE(S): LS ANSWER 37 OF ACCESSION NUMBER: TITLE: INVENTOR (S):

US 593-9602 19970107 8)
US 1993-9602 19930722 (8)
Continuation-in-part of Ser. No. US 1991-711334, filed continuation-in-part of Ser. No. US 1989-367894, filed DATE KIND NUMBER RELATED APPLN. INFO.: PATENT INFORMATION: INFO.: APPLICATION

on 19 Jun 1989, now abandoned which is a continuation-in-part of Ser. No. US 1989-361944, filled on Southuation-in-part of Ser. No. US 5504005 which is a continuation-in-part of Ser. No. US 5504005 which is a continuation-in-part of Ser. No. US 1988-213089, filled on 22 Jul 1988, now abandoned And a continuation-in-part of Ser. No. US 1988-16390, filled on 7 Jul 1988, now abandoned which is a continuation-in-part of Ser. No. US 1988-163546, filled on 3 Mar 1988, now abandoned which is a continuation-in-part of Ser. No. US 1987-20451, filled on 2 Mar 1987, now abandoned US 1987-20451, filled canted

Vogel, Nancy T. Hamilton, Brook, Smith & Reynolds, P.C.

20 Drawing Figure(s); 10 Drawing Page(s)

The present invention relates to recombinant mycobacteria, particularly recombinant M. bovis BCG, which express heterologous DNA encoding a product (protein or polypeptide) of interest, such a protein or polypeptide (e.g., an antigen) against which an immune response is desired or a cytokine. FILE SEGNENT: Granted
FILE SEAMINE: Granted
FILESAL REPRESENTATIVE: Hamilton, Brook, Smit
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
NUMBER OF DEALMINGS: 10
LINE COUNT: 1313
LINE COUNT: AMILABLE FOR THIS PATENT:
AB The present invention relates to recon

LS ANSWER 38 OF 46 ACCESSION NUMBER:

USPATFULL
96:113834 USPATFULL
Bacterial expression vectors containing DNA encoding secretion signals of lipoproteins
Stover, Charles K., Silver Spring, MD, United States MedImmune, Inc., Gaithersburg, MD, United States (U.S. IIIIE:

corporation) INVENTOR(S): PATENT ASSIGNEE(S):

US 5583038 19961210 (7) 1982-97-630 19921117 (7) Continuation-in-part of Ser. No. US 1991-780261, filed on 21 Oct 1991, now abandoned 19961210 DATE KIND PRIMARY EXAMINER: Granted PRIMARY EXAMINER: Fleisher, Mindy ASSISTANT EXAMINER: Carter, Philip W. LEGAL REPRESENTATIVE: Olstein, Elliot M. NUMBER OF CLAINS: 1 NUMBER OF DRAWINGS: 60 Drawing Figure(s); LINE COUNT: 2112
CAS INDEXING IS AVAILABLE FOR THIS PATENT. AB AN expression vector for survession. Granted Fleisher, Mindy Carter, Philip W. Olstein, Elliot M. NUMBER Utility RELATED APPLN. 'INFO. PATENT INFORMATION: APPLICATION INFO.: DOCUMENT TYPE:

An expression vector for expressing a protein or polypeptide in a harterium, which comprises a first DNA sequence encoding at least a secretion signal of a lipoprotein, and a second DNA sequence encoding a protein or fragment thereof, or polypeptide or peptide heterologous to the bacterium which expresses the protein or fragment thereof, or polypeptide or peptide. The bacterium expresses a fusion protein a lipoprotein or inpoprotein segment and the protein or fragment thereof, or polypeptide or peptide heterologous to the bacterium which expresses the protein or fragment thereof, or polypeptide or peptide. Such expression vectors increase the immunogenicity of the protein or fragment thereof, or polypeptide or peptide by enabling the protein or fragment thereof, or polypeptide or peptide to be expressed on the surface of the bacterium. Bacteria which may be transformed with the expression vector include mycobacteria such as BGG. The expression 60 Drawing Figure(s); 64 Drawing Page(s)

vectors of the present invention may be employed in the formation of live bacterial vaccines against Lyme disease wherein the bacteria express a surface protein of Borrelia burgdorferi, the causative agent of Lyme disease.

US 5580859
US 1994-215405
US 1994-215405
US 1997-215405
US 1997-215405
US 1997-215405
US 1992-315405
US 1992-45691, filed on 21 Mar 1990, now abandoned which is a division of Ser. No. US 1990-4467891, filed on 19 Jan 1990, now abandoned which filed on 19 Jan 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-326305, filed on 21 Mar 1989, now abandoned which is a continuation-in-part of Ser. No. US 1989-326305, filed on 21 Mar 1989, now abandoned 96:111449 USPATFULL
Delivery of exogenous DNA sequences in a mammal
Felgmer, Philip L., Rancho Santa Fe, CA, United States
Wolff, Jon A., Madison, WI, United States
Rhodes, Gary H., Leucadia, CA, United States
Malone, Robert W., Chicago, IL, United States
Carson, Dennis A., Del Mar, CA, United States
Carson, Dennis A., Del Mar, CA, United States
VICAL Incorporated, San Diego, CA, United States corporation) Wisconsin Alumni Research Foundation, Dane, WI, United States (U.S. corporation) 10 Drawing Figure(s); 9 Drawing Page(s) DATE Stone, Jacqueline M. Crouch, Deborah Knobbe, Martens, Olson & Bear KIND NUMBER Utility Granted USPATFULL APPLICATION INFO.: RELATED APPLN. INFO.: ASSISTANT EXAMINER: LEGAL REPRESENTATIVE: L5 ANSWER 39 OF 46 ACCESSION NUMBER: EXEMPLARY CLAIM: NUMBER OF DRAWINGS: PATENT ASSIGNEE(S): PATENT INFORMATION: NUMBER OF CLAIMS: PRIMARY EXAMINER: DOCUMENT TYPE: INVENTOR(S):

LINE COURT.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Polynucleotide sequences, comprising DNA and RNA molecules can be directly administered, for example by injection, to tissues, such as muscle, and expressed as a protein, polypeptide or polypeptide. The polynucleotides can be contained within liposomes or the polynucleotides can free from association with transfection-facilitating proteins, viral particles, liposomal formulations, charged lipids and calcium phosphate precipitating agents.

Cohen, Irun R., Rehovot, Israel
Blias, Dana, Rehovot, Israel
Markovits, Doron, Rehovot, Israel
Yeda Research and Development Co. Ltd., Rehovot, Israel
(non-U.S. corporation) 96:108677 USPATFULL Diagnosis and treatment of insulin dependent diabetes mellitus USPATFULL L5 ANSWER 40 OF 46 ACCESSION NUMBER: PATENT ASSIGNEE(S): INVENTOR (S):

US 5578303
US 1993-151052
US 1993-151052
US 1991-5148, filled on 29
Aug 1991, now abandoned which is a continuation-in-part
of Ser. No. US 1990-493127, filed on 14 Mar 1990, now DATE KIND NUMBER PATENT INFORMATION: APPLICATION INFO.: RELATED APPLN. INFO.:

abandoned which is a continuation-in-part of Ser. No. US 1989-37149, filled on 26 Jun 1989, now patented, Pat. No. US 5114844 which is a continuation-in-part of Ser. No. US 1989-322864, filled on 14 Mar 1989, now 11 Drawing Figure(s); 10 Drawing Page(s) Cunningham, Thomas M. LEGAL REPRESENTATIVE: Browdy and Neimark NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 11 Drawing Figure (e LINE COUNT: 1922
CAS INDEXING IS AVAILABLE FOR THIS PATENT. AB A 65 KD heat shock protein. abandoned Utility Granted PRIMARY EXAMINER:

A 65 MO heat shock protein, proteins cross-reactive therewith, antibodies therefor or T cells specific thereto can be used for detecting in humans the existence or T cells specific thereto can be used for detecting a process leading to insulin dependent diabetes mellitus. Antibodies to a process leading to insulin dependent diabetes mellitus. Antibodies to happes and to detect the happes molecule in blood or urine. The happes molecule of any species, or any other substance immunologically cross-reactive therewith, when administered with a tolerogenic carrier, and be used for the prevention or treatment of IDDM prior to development of claims a symptom thereof. T cells, active fragments thereof or the receptor peptide thereof can also be used for prevention or treatment of

USPATFULL
96:77659 USPATFULL
Expression of heterologous proteins in Drosophila cells
Johanese, Hanne R., Hojbjerg, Denmark
Van Der Straten-Ponthoz, Ariane A., Chicago, IL, United L5 ANSWER 41 OF 46 ACCESSION NUMBER: TITLE: INVENTOR(S):

States Rosenberg, Martin, Royersford, PA, United States(4) RolthKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)

PATENT ASSIGNEE(S)

DATE KIND NUMBER PATENT INFORMATION: APPLICATION INFO.: RELATED APPLN. INFO.:

US 5550043
US 1995-43178
US 1995-43178
US 1995-43178
US 1995-43178
US 1995-43178
US 1995-43178
US 1996-43178
US 1996-43178
US 1996-43178
US 1996-57453
US 1996-57453
US 1996-57453
US 27845454
US 1616d on 30 Oct 1989 which is a continuation of Ser. No. US 1990. now abandoned which is a continuation of Ser. No. US 1989-428454
US 1616d on 30 Oct 1989 which is a continuation of Ser. No. US 1987-47736, filed on 8 May

Elliott, George C. Sutton, Jeffrey A., Jervis, Herbert H., Lentz, Edward Utility PRIMARY EXAMINER: LEGAL REPRESENTATIVE: NUMBER OF CLAIMS: OCUMENT TYPE: SEGMENT

The present invention provides a novel method for expression of high levels of heterologous proteins in Drosophila cells. LINE COUNT:

LINE COUNT:

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The DEFERENT 'INTENT.

96:55678 USPATFULL In vitro activation of cytotoxic t-cells using insect cells expressing human class I MHC and USPATFULL ANSWER 42 OF 46 LS ANSWER 42 OF ACCESSION NUMBER:

Peterson, Per A., La Jolla, CA, United States Jackson, Michael, Del Mar, CA, United States Langlade-Demoyen, Pierre, Del Mar, CA, United States Scripps Research Institute, La Jolla, CA, United States (U.S. corporation) US 5529921 19960625 US 1994-209797 19940310 (8) Division of Ser. No. US 1992-841662, filed on 19 Feb 1992, now patented, Pat. No. US 5314813 25 Drawing Figure(s); 19 Drawing Page(s) DATE Adams, Donald E. Townsend and Townsend and Crew KIND beta.2-microglobulin 11NE COUNT:
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a NUMBER LEGAL REPRESENTATIVE: NUMBER OF CLAIMS: EXEMPLARY CLAIM: NUMBER OF DRAWINGS: RELATED APPLN. INFO.: PATENT INFORMATION: PATENT ASSIGNEE(S) PRIMARY EXAMINER DOCUMENT TYPE: INVENTOR (S) :

The present invention relates to a rational, elegant means of producing, loading and using Class I molecules to specifically activate CDB cells in vitro, and their therapeutic applications in the treatment of a variety of conditions, including cancer, tumors or neoplasias, as well as viral, retroviral, autoimmune, and autoimmune-type diseases. The present invention also relates to vectors, cell lines, recombinant DNA molecules encoding human. beta. 2 microglobulin or Class I MHC molecules in soluble and insoluble form, and methods of producing same.

ŢX, Gadicire, deceased, William L., late of San Antonio, Tr United States by John W. Robb, legal representative Clark, Garry M., San Antonio, TX, United States Channess, Gary C., San Antonio, TX, United States Tandon, Atul K., San Ramon, TX, United States Fuqua, Suzanne A., San Antonio, TX, United States Board of Regents. The University of Texas System, Austin, TX, United States (U.S. corporation) 95:80215 USPATFULL Heat shock/stress response proteins and prognosis in cancer LS ANSWER 43 OF 46 ACCESSION NUMBER: PATENT ASSIGNEE(S): INVENTOR (S)

PCT 371 date PCT 102(e) date 5 19921125 19910412 19921125 19921125 19950905 DATE US 5447843 WO 9116632 US 1992-949630 WO 1991-US2536 NUMBER PATENT INFORMATION: APPLICATION INFO.:

filed 20100223 Continuation-in-part of Ser. No. US 1990-509377, 3 00 12 Apr 1990, now patented, Pat. No. US 5188964 Utility DISCLAIMER DATE: RELATED APPLN. INFO.:

Scheiner, Toni R. Arnold, White & Durkee Granted 15 LEGAL REPRESENTATIVE: NUMBER OF CLAIMS: PRIMARY EXAMINER: EXEMPLARY CLAIM: DOCUMENT TYPE:

NUMBER OF DRAWINGS: 14 Drawing Figure ( LINE COUNT: 1371 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Drawing Figure(s); 6 Drawing Page(s)

The invention relates to a method of predicting disease-free survival in cancer patients by relating the number and amount of stress response proteins in cancer tissue to the probability of tumor recurrence.

Particular heat shock/stress response proteins useful in the determination of tumor recurrence are the stress response proteins useful in the App70, hsp27, and glucose regulated protein grp94. Specific levels of the stress response proteins relative to an internal strandard are identified, above which the probability of tumor recurrence is highly significant. Kit methods are disclosed which could enable determination of the stress proteins by an antibody assay. B

Peterson, Per A., LaJolla, CA, United States
Jackson, Michael, Del Mar, CA, United States
Langlade-Demoyen, Pierre, Del Mar, CA, United States
Scripps Research Institute, LaJolla, CA, United States Drosophila cell lines expressing genes encoding MHC class I antigens and B2-microglobulin and capable of assembling empty complexes and methods of making said 94:44555 USPATFULL (U.S. corporation) cell lines ANSWER 44 OF 46 USPATFULL PATENT ASSIGNEE(S): L5 ANSWER 44 OF ACCESSION NUMBER: TITLE: INVENTOR (S):

Hill, Jr., Robert J. Allen, Marianne P. Logan, April C., Liebeschuetz, Joe, Smith, William M. 24 Drawing Figure(s); 19 Drawing Page(s) 5 19940524 US 5314813 US 1992-841662 Granted PRIMARY EXAMINER:
ASSISTANT EXAMINER:
LEGAL REPRESENTATIVE:
UNIMBER OF CLAIMS:
EXEMPLARY CLAIM:
NUMBER OF DRAMINGS: PATENT INFORMATION: APPLICATION INFO.: DOCUMENT TYPE: LINE COUNT:

DATE

KIND

NUMBER

The present invention relates to a rational, elegant means of producing, loading and using Class I molecules to specifically activate CD8 cells in vitro, and their therapeutic applications in the treatment of a variety of conditions, including cancer, tumors or neoplasias, as well as viral, retroviral, autoimmune, and autoimmune-type diseases. The present invention also relates to vectors, call lines, recombinant DNA molecules encoding human. beta. 2 microglobulin or Class I MHC molecules in soluble and insoluble form, and methods of producing same. CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a

93:100493 USPATFULL
INSECT specific paralytic neurotoxin genes for use in plotogical insect control: methods and compositions Tomalski, Michael D., Athens, GA, United States Miller, Lois K., Athens, GA, United States Miller, Lois K., Athens, GA, United States Athens, GA, United States Athens, GA, United States (U.S. corporation) USPATFULL ANSWER 45 OF L5 ANSWER 45 OF ACCESSION NUMBER: INVENTOR (S):

PATENT ASSIGNEE(S):

0 19931130 KIND US 1990-593657 US 1990-593657 Utility Granted NUMBER PATENT INFORMATION: APPLICATION INFO.: DOCUMENT TYPE:

Greenlee and Winner Furman, Keith C. Wax, Robert A. ASSISTANT EXAMINER: LEGAL REPRESENTATIVE: PRIMARY EXAMINER:

Genes encoding insect-specific paralytic neurotoxins, particularly those of insect-parasitic mites, including Pyemotes, are described.

Of insect-parasitic mites, including Pyemotes, are described.

Becombinant DNA molecules in which the neurotoxin coding sequences are placed under the control of heterologous promoters are also described. Such molecules are useful for the development of biological insect control agents which produce insect-toxic levels of the neurotoxin. Specifically described are genetically altered baculoviruses which produce insect-specific paralytic neurotoxins and which display improved toxic effect on insects. Insect-toxic compositions are also provided. Described insect control using these neurotoxin genes, methods for production of neurotoxins in cells, and methods of production of insect control agents are described. 1 9 Drawing Figure(s); 9 Drawing Page(s) LINE COUNT: 2085
CAS INDEXING IS AVAILABLE FOR THIS PATENT. NUMBER OF CLAIMS: EXEMPLARY CLAIM: NUMBER OF DRAWINGS:

Method and kit for the prognostication of breast cancer bethod and kit for the prognostication of breast cancer patient via heat shock/stress protein determination McGuire, William L., San Antonio, TX, United States Tandon, Atul K., San Antonio, TX, United States Clark, Gary M., San Antonio, TX, United States Chamness, Gary C., San Antonio, TX, United States Board of Regents, The University of Texas System, Austin, TX, United States 14 Drawing Figure(s); 6 Drawing Page(s) 5 19900412 19930223 Housel, James C. Chan, William Arnold, White & Durkee EXEMPLARY CLAIM:

NUMBER OF DRAWINGS:
14 Drawing Figure (ELINE COUNT:
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a method of US 5188964 US 1990-509377 Utility NUMBER Granted ASSISTANT EXAMINER: LEGAL REPRESENTATIVE: NUMBER OF CLAIMS: ANSWER 46 OF 46 PATENT ASSIGNEE(S): PATENT INFORMATION: APPLICATION INFO.: DOCUMENT TYPE: L5 ANSWER 46 OF ACCESSION NUMBER: TITLE: PRIMARY EXAMINER INVENTOR(S):

=> d his

(FILE 'HOME' ENTERED AT 07:31:47 ON 11 SEP 2002)

The invention relates to a method of predicting disease-free survival cancer patients by relating the number and amount of stress response proteins in the cancer Lissue to the probability of tumor recurrence. Particular heat shock/stress response proteins useful in the determination of tumor recurrence are the stress response proteins, bgp70, hsp90, hsp27, and glucose regulated protein grp94. Specific levels of the stress response protein grp94 which the probability of tumor recurrence is highly significant. Kit methods are disclosed which could enable determination of the stress proteins by an antibody assay.

'USPATFULL' ENTERED AT 07:32:03 ON 11 S 820 S HSP70 OR HEAT SHOCK PROTEIN 70 340 S L1 AND ADUVANT 340 DUP REM L2 (0 DUPLICATES REMOVED) 340 S L3 FILE 4224

L5 46 S L3 NOT Pt=>1999		NCLS, EXF, REP
-> s l2 and pharmaceutic	arada	PARN, SUMM, DRI
		RLI, PRAI, REP
1309 PHARMACEUTICS 1800 PHARMACEUTIC	FHITSTR	HIT RN, its te
(PHARMACEUTIC OR PHARMACEUTICS)	FPG	FP plus PAGE.D
L6 0 L2 AND PHARMACEUTIC	IS	PN and page im
A fi	HITTEN	All fields con
	HITSTR	HIT RN, its ter
=> \$ 12 and pharmaceutical?		its structure
144435 FARMARECITICAL: 1.7 266 1.2 AND PHARMARETTOR:	IABS	ABS, indented
	IALLG	IALL, DINSERLED
e> 8 17 and cancer		BIB, indented
52128 CANCER 15572 CANCERS	IBIB.EX	IBIB for origin
3	IMAX	MAX, indented w
	IMAX.EX	IMAX for origin
La 210 L/ AND CANCEK	IND	INCL, INCLM, IN
-> 8 18 and administer?		STD, indented
142584 ADMINISTRATION		All hit terms
	MAX	AN, TI, IN, IN,
-> S 19 and treat?		DRWN, AB, GOVI
787080 TEEAT?		INCLM, INCLS, I
	2	EXF, ARTU OS,
=> S 110 not py=>1999		MAA tor originatist of display
8160		AN, TI, IN, IN
L11 14 L10 NOT PX=>1999	Nego	DI, FS, LN.CNT
-> d 1-14 ibib and ab	SCAIN TELEVISION	without answer
'AND' IS NOT A VALID FORMAT FOR FILE 'USPATFULL'		same line as D
The following are valid formats:	STD	AN, TI, IN, IN
		IC, ICM, ICS,
The default display format is STD.	STD.EX	STD for origina
ABS AB	TRIAL	AN, TI, INCL,
		LCM, ICS
	ENTER DISPLAY	ENTER DISPLAY FORMAT (STD) :
DRINI, AB, GOVI, PARN, SUMM, DRUD, DETD, CLM, INCL,		
EXF. ARTU	=> d nis	
3 ALL plus PAGE.DRAW	(FILE 'H	(FILE 'HOME' ENTERED A'
BIBAN, IT, IN, INA, PA, PAA, PAT, PI, AI, PTERN, DCD, RLI. DDAI DT DC DVANAM IDDD CTMY DCT NOWD IN COMMENTAL		
	בוו אווא יונו	USPATFULL' ENTER
		40 S LI AND AD
BROWSE See "HELP BROWSE" or "HELP DISPLAY BROWSE". BROWSE must	1.3	340 DUP REM L2
entered on the same line as DISPLAY, e.g., D BROWSE.	m	340 S L3
	2.1 9.1	46 S L3 NOT PY: 0 S L2 AND PH
		266 S L2 AND PH
FF	1.8	210 S L7 AND CA
NCL, NCL, EXP, REP, REP, REV, BYNAM, IREP,	N 69	ດທ
;	L11	14 S LIO NOT P
FPALL PI, TI, IN, INA, PA, PAA, PAT, PETRM, DCD, AI,	=> d 111 1-14 ibib ab	ibib ab
RLI, PRAI, IC, ICM, ICS, INCL. INCL. INCL. NOT.	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	

LII ANSWER I OF 14 USPATFULL	USPATFULL
ACCESSION NUMBER:	1998:151078 USPATFULL
TITLE:	Vertebrate embryonic pattern-inducing proteins, and
	uses related thereto
INVENTOR (S):	Ingham, Philip W., Summertown, England
	McMahon, Andrew P., Lexington, MA, United States
	Tabin, Clifford J., Cambridge, MA, United States
PATENT ASSIGNEE(S):	President and Fellows of Harvard College, Cambridge,
	MA, United States (U.S. corporation)

DATE

KIND

	****	
PATENT INFORMATION:	US 5844079 1998	19981201
APPLICATION INFO.:	US 1994-356060 1994	19941214 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1993-176427, filed	No. US 1993-176427, filed
	on 30 Dec 1993	
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Walsh, Stephen	
ASSISTANT EXAMINER:	Sorensen, Kenneth H.	
LEGAL REPRESENTATIVE:	Vincent, Matthew P., Arnold, Beth E.Foley, Hoad & Eliot	Beth E.Foley, Hoad & Eliot
	LLP	
NUMBER OF CLAIMS:	41	
EXEMPLARY CLAIM:	-	
NUMBER OF DRAWINGS:	22 Drawing Figure(s); 21 Drawing Page(s)	(wing Page(s)
LINE COUNT:	7618	· ·
CAS INDEXING IS AVAILABLE FOR THIS PATENT.	BLE FOR THIS PATENT.	
AB The present inve	The present invention concerns the discovery that proteins encoded by a	that proteins encoded by a

IE COUNT:

INDEXING IS AVAILABLE FOR THIS PATENT.

The present invention concerns the discovery that proteins encoded by a family of vertebrate genes, termed here hedgehog-related genes, comprise morphogenic signals produced by embryonic patterning centers, and are involved in the formation of ordered spatial arrangements of differentiated tissues in vertebrates. The present invention makes available compositions and methods that can be utilized, for example to generate and/or maintain an array of different vertebrate tissue both in vitro and in vivo.

USPATFULL 1998:143661 USPATFULL	Compositions and methods using complexes of heat proteins and antiqenic molecules for the	treatment and prevention of neoplastic diseases Srivastava Pramod K. Riverdale Ny United Stat	Fordham University, Bronx, NY, United States (U.S. corporation)
LII ANSWER 2 OF 14 USPATFULL ACCESSION NUMBER: 1998:14	TITLE:	INVENTOR (S):	PATENT ASSIGNEE(S):

shock

tes S.

DATE

KIND

PATENT INFORMATION:	US 5837251	19981117	
APPLICATION INFO.:	US 1995-527391	19950913 (8)	
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Feisee, Lila		
ASSISTANT EXAMINER:	Bansal, Gee Tha D.		
LEGAL REPRESENTATIVE:	Pennie & Edmonds LLP		
NUMBER OF CLAIMS:	33		
EXEMPLARY CLAIM:	1,8,16		
NUMBER OF DRAWINGS:	18 Drawing Figure(s): 8 Drawing Page(s)	Drawing Page(s)	
LINE COUNT:	2361		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.	LE FOR THIS PATENT.		

The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases. The methods of the invention comprise administering a composition comprising an effective amount of a complex, in which the complex Æ

US 1994-18409
US 1994-18409
US 1994-18409
Continuation-in-part of Ser. No. US 1993-7115, filed on continuation-in-part of Ser. No. US 1992-847951, filed on 6 Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-847951, filed on 6 Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-713967, filed on 11 Jun 1991, now abandoned which is a

DATE

KIND

NUMBER

PATENT ASSIGNEE(S):

INVENTOR(S):

PATENT INFORMATION: APPLICATION INFO.: RELATED APPLN. INFO.:

1998:138427 USPATFULL
Canarypox virus expressing cytokine and/or
tumor-associated antigen DNA sequence
Paoletti, Enzo, Delmar, NY, United States
Tartaglia, James, Schenectady, NY, United States
Cox, William I., Troy, NY, United States
Virogenetics Corporation, Troy, NY, United States
corporation)

USPATFULL

L11 ANSWER 4 OF 14 ACCESSION NUMBER: TITLE:

consists essentially of a heat shock protein (hsp) noncovalently bound to an antigenic molecule. "Antigenic molecule" as used herein refers to the peptides with which the hsps are endogenously associated in vivo as well as exogenous that which the hsps are endogenously associated in vivo as complex at a sutologous to the thereof. In a preferred embodiment, the complex is autologous to the individual. The effective amounts of the complex are in the range of 10.600 micrograms for nsp9, and 10.600 micrograms for hsp9, and 10.600 micrograms for hsp9, and 10.600 micrograms for hsp9, and 10.600 micrograms for provides a method for measuring tumor rejection in vivo in an individual, preferably a human, comprising measuring the generation by the individual of MEC class I-restricted CD8+ cytotoxic T lymphocytes specific to the tumor. Methods of purifying hsp70-peptide

USPATFULL 1998:138682 USPATFULL POLynuclectides encoding a cofactor A-like protein Hillman, Jennifer L., San Jose, CA, United States Goli, Surya K., Sunnyvale, CA, United States Incyte Pharmaceuticals, Inc., Palo Alto, CA, United States (U.S. corporation)	NUMBER KIND DATE	19981110	US 1597-025/02 159/U4U8 (8) Utility Granted	Kemmerer, Elizabeth C. Romeo, David S.		9	3 Drawing Figure(s); 3 Drawing Page(s) 1933	CAS INDEXING IS AVAILABLE FOR THIS PATENT.	The present invention provides a human cofactor A-like protein (COAPR) and polynucleotides which identify and encode COAPR. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of COAPR.
L11 ANSWER 3 OF 14 ACCESSION NUMBER: TITLE: INVENTOR(S): PATENT ASSIGNEE(S):		PATENT INFORMATION:	AFFLICATION INFO:: DOCUMENT TYPE: FILE SEGMENT:	PRIMARY EXAMINER: ASSISTANT EXAMINER:	LEGAL REPRESENTATIVE:	NUMBER OF CLAIMS: EXEMPLARY CLAIM:	NUMBER OF DRAWINGS: LINE COUNT:	CAS INDEXING IS AVAI	AB The present i and polynucle provides eartagoniers. disorders ass

continuation-in-part of Ser. No. US 1991-666056, filed on 7 Mar 1991, now abandoned, said Ser. No. US 7115 which is a continuation-in-part of Ser. No. US 7115 1991-805567, filed on 16 Dec 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-80800, filed on 7 Jan 1991, now abandoned, said Ser. No. US 7115 which is a continuation-in-part of Ser. No. US 1992-847977, filed on 3 Mar 1992, now abandoned which is a division of Ser. No. US 1990-478779, filed on 14 Feb 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-320471, filed on 8 Mar 1989, now patented, Pet. No. US 5155020

PRIMARY EXAMINER: SEGMENT:

Crouch, Deborah Frommer Lawerence & Haug LLP, Frommer, William S., Kowalski, Thomas J. LEGAL REPRESENTATIVE:

USPATFULL ANSWER 5 OF 14

LII ANSWER 5 OF 1 ACCESSION NUMBER: TITLE:

1998:134628 USPATFULL Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination

with adoptive immunotherapy Srivastava, Pramod K., Riverdale, NY, United States Fordham University, Bronx, NY, United States (U.S. INVENTOR(S): PATENT ASSIGNEE(S):

KIND corporation) NUMBER

DATE

PATENT INFORMATION: US 5830464

DOCUMENT TYPE: Utility
Canted
PRIMARY EXAMINER: Saunders, David
ASSISTANT EXAMINER: Saunders, David
ASSISTANT EXAMINER: VanderVegt, F. Pierre
LEGAL REPRESENTATIVE: Pennie & Edmonds LLP
LEGAL REPRESENTATIVE: Pennie & Edmonds LLP
LEGAL REPRESENTATIVE: Pennie & Edmonds LLP
LEGAL REPRESENTATIVE: Dennie & Edmonds LLP
LEGAL REPRESENTATIVE: Dennie & Edmonds LLP
LINE COUNT: 1332
CAS INDEXING IS AVAILABLE FOR THIS PATENT
AB The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases. The methods of the invention comprise administering a composition comprise administering a composition with administering consists essentially of a heat shock protein (hsp) noncovalently bound to an antigenic molecule. "Antigenic molecule" as used herein

refers to the peptides with which the haps are endogenously associated in vivo as well as exogenous antigens/immunogens (i.e., with which the haps are not complexed in vivo) or antigenic/immunogenic fragments and derivatives thereof. In a preferred embodiment, the complex is autologous to the individual. In a specific embodiment, the effective amounts of the complex when administered intradermally are in the range of 0.1 to 9.0 micrograms for complexes comprising hap70, 5 to 49 micrograms for hap90, and 0.1 to 9.0 micrograms for space in another embodiment, the effective amounts of the complex when administered subcutaneously are in the range of 10 to 600 micrograms for complexes comprising hap70, 50 to 5000 micrograms for complexes comprising hap70, 50 to 5000 micrograms for hap90, and 10 to 600 micrograms for gp96.

USPATFULL ANSWER 6 OF 14 L11 ANSWER 6 OF 1 ACCESSION NUMBER:

INVENTOR (S):

Heat shock-like protein
Hallman, Jennifer L., San Jose, CA, United States
Shah, Purvi, Sunnyvale, CA, United States
Incyce Pharmaceuticals, Inc., Palo Alto, CA, United
States (U.S. corporation) PATENT ASSIGNEE(S):

5 Drawing Figure(s); 4 Drawing Page(s) 8 19980929 DATE KIND ASSISTANT EXAMINER: Bugalsky, Gabriele E.
LEGAL REPRESENTATIVE: Billings, Lucy J.
NUMBER OF CLAINS: 8
NUMBER OF CLAINS: 8
NUMBER OF CLAINS: 5
Drawing Figure(8); ill NUMBER OF DRAWINGS: 5 Drawing Figure(8); ill NUMBER OF NAVILABLE FOR THIS PATENT.
AB The present invention provides a con-Wax, Robert A. Bugalsky, Gabriele E. Billings, Lucy J. US 1997-846134 Utility NUMBER Granted PATENT INFORMATION: APPLICATION INFO.: DOCUMENT TYPE: PRIMARY EXAMINER FILE SEGMENT:

The present invention provides a novel heat shock-like protein (HSPRO) and polynucleotides which identify and encode HSPRO. The invention also provides expression vectors, host cells, agonists, antibodies, and antagonists. The invention also provides methods for treating disorders associated with expression of HSPRO.

USPATFULL

1998:111956 USPATFULL
Inhibitors of IMPBH enzyme
Armistead, David M., Maynard, MA, United States
Badia, Michael C., Bedford, MA, United States
Badia, Michael C., Aldford, MA, United States
Bennis, Guy W., Arlington, MA, United States
Bernis, Catharine A., Marlborough, MA, United States
Novak, Perry M., Milford, MA, United States
Ronkin, Steven M., Watertown, MA, United States
Saunders, Jeffrey O., Atcon, MA, United States
Vertex Pharmaceuticals Incorporated, Cambridge, MA,
United States (U.S. corporation) L11 ANSWER 7 OF 14 ACCESSION NUMBER: INVENTOR (S):

PATENT ASSIGNEE(S):

DATE

NUMBER

8 US 5807876 US 1996-636361 Granted PRIMARY EXAMINER: ASSISTANT EXAMINER: LEGAL REPRESENTATIVE: PATENT INFORMATION: APPLICATION INFO.: DOCUMENT TYPE: FILE SEGMENT:

Shah, Mukund J. Kifle, Bruck Fish & Neave, Haley, Jr., James F., Govindaswamy, N.

NUMBER OF CLAIMS: 21
EXENELARY CLAIM: 194
LINE COUNT: 1494
LAINE COUNT.
AB THE PRESENT INVENTION RELEASE to a novel class of compounds which are morphisticns. This invention also relates to pharmaceutical compositions compositions of this invention also relates to pharmaceutical compositions of this invention are particularly well suited for inhibiting iMPDH enzyme activity and consequently. Well suited for inhibiting iMPDH enzyme activity and consequently well suited for inhibiting iMPDH enzyme activity and consequently well such a spense for immunosuppression. This invention also relates to methods for inhibiting the activity of IMPDH using the compounds of this invention and related compounds. USPATFULL ANSWER 8 OF 14

1998:101540 USPATFULL Human protein disulfide isomerase Braxton, Soott Michael, San Mateo, CA, United States Murry, Lynn E., Pótrola Valley, CA, United States Incyte Pharmaceuticals, Inc., Palo Alto, CA, United States (U.S. corporation) PATENT ASSIGNEE(S): L11 ANSWER 8 OF A INVENTOR (S):

DATE KIND NUMBER PATENT INFORMATION: APPLICATION INFO.: RELATED APPLN. INFO.:

US 5792249 US 1996-650275 US 1996-650275 Continuation-in-part of Ser. No. US 1996-649740, filed On 15 May 1996 Utility 13 Drawing Figure(s); 13 Drawing Page(s) LEGAL REPRESENTATIVE: SAIGNA, TEXCRAND
LEGAL REPRESENTATIVE: Billings, Lucy J.
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 13 Drawing Figure:
LINE COUNT: 2291
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides a no Wax, Robert A. Saidha, Tekchand Billings, Lucy J. Granted Wax, Rob FILE SEGMENT: PRIMARY EXAMINER: ASSISTANT EXAMINER:

pharmaceutical compositions for the treatment of diseases associated with the abnormal expression of PDIH. Additionally, the invention provides for the use of antiseases molecules to pdih or inhibitors of PDIH in pharmaceutical compositions for treatment of diseases resulting secretion of PDIH. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, fragments or the complement thereof, which hybridize with the genomic sequence or the transcript of pdih, or anti-PDIH antibodies which specifically bind to the polypeptide, PDIH. The present invention provides a polynucleotide (pdih) the partial sequence for which was initially isolated from a lung cDNA library and which identifies and encodes a novel human protein disulfide isomerase (PDIH). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding PDIH. The invention also provides for the use of purified PDIH and its agonists in the commercial production of recombinant proteins and in

1998:92162 USPATFULL USPATFULL L11 ANSWER 9 OF 14 ACCESSION NUMBER:

Vertebrate embryonic pattern-inducing proteins and uses related thereto Transcu instruction of Summertown, England McMahon, Andrew P., Lexington, MA, United States Tabin, Clifford J., Cambridge, MA, United States President and Fellows of Harvard College, Cambridge, MA, United States (U.S. corporation) PATENT ASSIGNEE(S): INVENTOR(S):

DEXING IS AVAILABLE FOR THIS PATENT.

The present invention concerns the discovery that proteins encoded by a family of vertebrate genes, termed here hedgehog-related genes, comprise morphogenic signals produced by embryonic patterning centers, and are involved in the formation of ordered spatial arrangements of differentiated tissues in vertebrates. The present invention makes available compositions and methods that can be utilized, for example to generate and/or maintain an array of different vertebrate tissue both in Walsh, Stephen Sorensen, Kenneth A. Vincent, Matthew P., Arnold, Beth E.Foley, Hoag & Eliot LLP 12 Drawing Figure(s); 15 Drawing Page(s) 8 19980804 DATE KIND US 5789543 US 1993-176427 Utility Granted NUMBER 4235 EXEMPLARY CLAIM:

NUMBER OF DRAWINGS:

LINE COUNT:

CAS INDEXING IS AVAILABLE R

AB The present invention vitro and in vivo. LEGAL REPRESENTATIVE: INFORMATION: PRIMARY EXAMINER: ASSISTANT EXAMINER: APPLICATION INFO.: NUMBER OF CLAIMS: DOCUMENT TYPE: FILE SEGMENT:

USPATFULL

1998:88652 USPATFULL
Therapeutic and diagnostic methods and compositions
Therapeutic and diagnostic methods and compositions
Therapeutic and diagnostic methods actids
Therapeutic systiding, Hamden, CT, United States
Rehon, Richard Grant, Durham, NC, United States
Fehon, Richard Grant, Durham, NC, United States
Zagouras, Panayiotis, New Haven, CT, United
Blaumueller, Christine Marie, New Haven, CT, United US 5786158
US 1993-83590
US 1993-83590
US 1993-83590
US 1993-83590
US 1992-955012, filed
On 30 Sep 1992, now abandoned And a
continuation-in-part of Ser. No. US 1992-879038, filed
Utility
Granted States Yale University, New Haven, CT, United States (U.S. corpozation) 19980728 DATE KIND NUMBER APPLICATION INFO.: RELATED APPLN. INFO.: L11 ANSWER 10 OF 14 ACCESSION NUMBER: TITLE: PATENT ASSIGNEE(S): PATENT INFORMATION: DOCUMENT TYPE: INVENTOR (S):

70 Drawing Figure(s); 68 Drawing Page(s) LINE COUNT:
CAS INDEXING IS AVAILABLE FOR THIS PATENT:
AB The present invention relates to di LEGAL REPRESENTATIVE: NUMBER OF CLAIMS: EXEMPLARY CLAIM: NUMBER OF DRAWINGS:

Scheiner, Toni R. Pennie & Edmonds LLP 9

PRIMARY EXAMINER

The present invention relates to diagnostic methods and compositions for detection of malignancy or nervous system disorders based on the level of Notch proteins or nucleic acids. Therapeutic methods and methods of inhibiting Notch expression are also provided

Deltex proteins Artavania-Taskonas, Spyridon, Hamden, CT, United States Busseau, Isabelle, Bures-Sur-Yvette, France Diederich, Robert J., New Haven, CT, United States USPATFULL 1998:51728 USPATFULL L11 ANSWER 11 OF 14 ACCESSION NUMBER: INVENTOR (S):

Xu, Tian, Guilford, CT, United States Matsuno, Kenji, New Haven, CT, United States Tele University, New Haven, CT, United States (U.S. corporation) PATENT ASSIGNEE(S):

	NUMBER	KIND	DATE			
		-				
PATENT INFORMATION:	US 5750652		19980512			
APPLICATION INFO.:	US 1994-185432		19940121	(8)		
DOCUMENT TYPE:	Utility					
FILE SEGMENT:	Granted					
PRIMARY EXAMINER:	Walsh, Stephen					
ASSISTANT EXAMINER:	Sorensen, Kenneth A.	:				
LEGAL REPRESENTATIVE:	Pennie & Edmonds LLP	Q.				
NUMBER OF CLAIMS:	27					
EXEMPLARY CLAIM:	1					
NUMBER OF DRAWINGS:	58 Drawing Figure(s); 40 Drawing Page(s)	); 4(	Drawing	Page (s)	_	
LINE COUNT:	4194		1	•		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.	BLE FOR THIS PATENT.					
AB The present inv	The present invention relates to amino acid sequences of the encod	no ac	cid sequen	ces of	the	encod

BANDIABLE FOR THIS PATENT.

The present invention relates to amino acid sequences of the encoded deltex protein. The invention further relates to fragments and other deltex protein. The invention further relates to fragments and other the invention relates to deltex proteins. In specific embodiments, the invention which are functionally active, or which comprise one or more domains of a deltex protein, including but not limited to the Gin-rich clusters, SH3 binding domains, domains which mediate binding to Notch or tepeats, domains which mediate binding to Notch or prepats, domains which mediate binding to Notch or any combination of the foregoing. The present invention also relates to compositions based on deltex proteins.

		Immunotherapeutic stress protein-peptide complexes against cancer	Srivastava, Pramod K., Riverdale, NY, United States	Of The City University	of New York, New York, NY, United States (U.S. corporation)	
		ss protei	Riverda]	Medicine	NY, Unit	DATE
	USPATFULL	peutic stre	Pramod K.,	School of	, New York,	KIND
USPATFULL	1998:51204 USPATFULL	Immunotheral	Srivastava,	Mount Sinai	of New York, corporation)	NUMBER
9 14						
L11 ANSWER 12 OF 14 USPATFULL	ACCESSION NUMBER:	TITLE:	INVENTOR (S):	PATENT ASSIGNEE(S):		

------19980512 19940330 (8) Ser. No. US 1994-180685, filed US 5750119 US 1994-315892 Continuation-in-part of on 13 Jan 1994 Feisee, Lila Bansal, Geetha P. Pennie & Edmonds LLP on 13 Ja Utility Granted PATENT INFORMATION: APPLICATION INFO.: RELATED APPLN. INFO.: LEGAL REPRESENTATIVE: ASSISTANT EXAMINER: FILE SEGMENT: PRIMARY EXAMINER: DOCUMENT TYPE:

NUMBER OF CIAIMS:

1.2

LINE COUNT:

1.2

LINE COUNT:

1.2

LINE COUNT:

1.2

LINE COUNT:

1.2

AB DISCLOSEd is a method for inhibiting the proliferation of a tumor in a mammal. The method involves the steeps of (a) isolating a stress protein-peptide complex from tumor cells previously removed from the mammal and (b) administering the isolated stress protein-peptide complex back to the mammal in order to stimulate in the mammal an immune response against the tumor from which the complex was isolated. Stress protein-peptide complexe such service of the instant invention include the Happon the practice of the instant invention include the Happon tuility in the prettide, Happon-peptide and gp96-peptide complexes.

ASSISTANT ACCOUNT.

LEGAL REPRESENTATIVE:

NUMBER OF CLAINS:

SERBINGS INDEX OF DRAWINGS:

6 Drawing Figure(8); 3 Drawing Page(8)

LINE COUNT:

AN autocrine crystal adhesion inhibitor called CAI is an anionic, sialic acid-containing glycoprotein secreted by kidney epithelial calls that allocks adhesion of calcium oxalate monohydrate (COM) crystals that blocks adhesion of calcium oxalate monohydrate (COM) crystals to the call surfaces. Persons may be classified according to risk of developing kidney stones, by measuring the amount of CAI in a biological sample.

Treatment efficacy is also monitored by this method. CAI is administered in vivo to prevent nephrolithiasis. A rapid, simple assay to detect agents that inhibit adhesion of COM crystals to the surface of kidney epithelial cells is characterized. Methods and compositions for detecting and treating kidney diseases associated with adhesion of crystals to kidney cells Toback, F. Gary, Chicago, IL, United States Lieske, John C., Evanston, IL, United States States (W.S. Corporation, Chicago, IL, United States States (U.S. corporation) <u>8</u> 19970408 DATE KIND US 5618917 US 1995-389005 Utility Granted Nucker, Christine M. Reeves, Julie E. 97:29572 USPATFULL NUMBER L11 ANSWER 13 OF 14 ACCESSION NUMBER: PATENT ASSIGNEE(S): PATENT INFORMATION: ASSISTANT EXAMINER: APPLICATION INFO.: DOCUMENT TYPE: PRIMARY EXAMINER: SEGMENT: INVENTOR (S):

corporation)
Wisconsin Alumni Research Foundation, Dane, WI, United States (U.S. corporation) (U.S. States Delivery of exogenous DNA sequences in a mammal Delivery of exogenous DNA sequences in a mammal Felgner, Philip L., Rancho Santa Fe, CA, United St Wolff, Jon A., Madison, WI, United States Rhodes, Gary H., Leucadia, CA, United States Carson, Dennis A., Del Mar. CA, United States VICAL Incorporated, San Diego, CA, United States DATE KIND NUMBER USPATFULL 14 PATENT ASSIGNEE(S): LII ANSWER 14 OF
ACCESSION NUMBER: INVENTOR (S):

US 5580859
US 1994-215405
US 1994-215405
19940318 (8)
1992. now of Ser. No. US 1992-846827, filed on 6 Mar 1990. 496991, filed on 21 Mar 1990, now abandoned which is a division of Ser. No. US 1990-496991, filed on 21 Mar 1990, now abandoned which is a continuation-in-part of Ser. No. US 1990-467881, filed on 19 Jan 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-326305, filed on 21 Mar 1989, now abandoned Stone, Jacqueline M. Crouch, Deborah Knobbe, Martens, Olson & Bear Granted PATENT INFORMATION: APPLICATION INFO.: RELATED APPLN. INFO.: LEGAL REPRESENTATIVE PRIMARY EXAMINER: ASSISTANT EXAMINER: DOCUMENT TYPE: FILE SEGMENT:

EXEMPLARY CLAIM:

1 Drawing Figure(s); 9 Drawing Page(s)

2 S72

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB POLYNUCIOCITÉ S equences, compirising DNA and RNA molecules can be directly administered, for example by injection, to tissues, such as muscle, and expressed as a protein, polypeptide or polypeptide.

The polynuciocitées can be contained within liposomes on the polynuciectides can free from association with transfection-facilitating proteins, viral particles, liposomal formulations, charged lipids and calcium phosphate precipitating agents.

and the second of the second o

The state of the s